{
    "abstract": "The currently fielded pre-hospital therapeutic regimen for the treatment of organophosphorus (OP) poisoning in the United States (U.S.) is the administration of atropine in combination with an oxime antidote (2-PAM Cl) to reactivate inhibited acetylcholinesterase (AChE). Depending on clinical symptoms, an anticonvulsant, e.g., diazepam, may also be administered. Unfortunately, 2-PAM Cl does not offer sufficient protection across the range of OP threat agents, and there is some question as to whether it is the most effective oxime compound available. The objective of the present study is to identify an oxime antidote, under standardized and comparable conditions, that offers protection at the FDA approved human equivalent dose (HED) of 2-PAM Cl against tabun (GA), sarin (GB), soman (GD), cyclosarin (GF), and VX, and the pesticides paraoxon, chlorpyrifos oxon, and phorate oxon. Male Hartley guinea pigs were subcutaneously challenged with a lethal level of OP and treated at approximately 1min post challenge with atropine followed by equimolar oxime therapy (2-PAM Cl, HI-6 DMS, obidoxime Cl2, TMB-4, MMB4-DMS, HL\u00f6-7 DMS, MINA, and RS194B) or therapeutic-index (TI) level therapy (HI-6 DMS, MMB4-DMS, MINA, and RS194B). Clinical signs of toxicity were observed for 24h post challenge and blood cholinesterase [AChE and butyrylcholinesterase (BChE)] activity was analyzed utilizing a modified Ellman's method. When the oxime is standardized against the HED of 2-PAM Cl for guinea pigs, the evidence from clinical observations, lethality, quality of life (QOL) scores, and cholinesterase reactivation rates across all OPs indicated that MMB4 DMS and HL\u00f6-7 DMS were the two most consistently efficacious oximes.",
    "author_highlights": [
        {
            "endOffset": 21897,
            "sentence": "First comprehensive evaluation of leading AChE oxime reactivators",
            "startOffset": 21832
        },
        {
            "endOffset": 21960,
            "sentence": "All oximes are compared against current U.S. therapy 2-PAM Cl.",
            "startOffset": 21898
        },
        {
            "endOffset": 22029,
            "sentence": "Relative therapeutic oxime efficacies against OP CWNA and pesticides",
            "startOffset": 21961
        },
        {
            "endOffset": 22108,
            "sentence": "Contribution to more effective antidotes for civilian and military populations",
            "startOffset": 22030
        }
    ],
    "bib_entries": {
        "bb0005": {
            "authors": [
                {
                    "first": "Biljana",
                    "initial": "B.",
                    "last": "Antonijevic"
                },
                {
                    "first": "Milos P.",
                    "initial": "M.P.",
                    "last": "Stojiljkovic"
                }
            ],
            "doi": "10.3121/cmr.2007.701",
            "firstpage": "71",
            "issn": "15394182",
            "lastpage": "82",
            "pmid": "17456837",
            "pub_year": 2007,
            "title": "Unequal efficacy of pyridinium oximes in acute organophosphate poisoning",
            "volume": "5"
        },
        "bb0010": {
            "authors": [
                {
                    "first": "B. M.",
                    "initial": "B.M.",
                    "last": "ASKEW"
                }
            ],
            "doi": "10.1111/j.1476-5381.1956.tb00009.x",
            "firstpage": "417",
            "issn": "03660826",
            "lastpage": "423",
            "pmid": "13383120",
            "pub_year": 1956,
            "title": "Oximes and hydroxamic acids as antidotes in anticholinesterase poisoning",
            "volume": "11"
        },
        "bb0015": {
            "authors": [
                {
                    "first": "Fatma Goksin",
                    "initial": "F.G.",
                    "last": "Bahar"
                },
                {
                    "first": "Kayoko",
                    "initial": "K.",
                    "last": "Ohura"
                },
                {
                    "first": "Takuo",
                    "initial": "T.",
                    "last": "Ogihara"
                },
                {
                    "first": "Teruko",
                    "initial": "T.",
                    "last": "Imai"
                }
            ],
            "doi": "10.1002/jps.23258",
            "firstpage": "3979",
            "issn": "00223549",
            "lastpage": "3988",
            "pmid": "22833171",
            "pub_year": 2012,
            "title": "Species difference of esterase expression and hydrolase activity in plasma",
            "volume": "101"
        },
        "bb0020": {
            "authors": [
                {
                    "first": "Jir\u00ed",
                    "initial": "J.",
                    "last": "Bajgar"
                }
            ],
            "doi": "10.1016/S0065-2423(04)38006-6",
            "firstpage": "151",
            "issn": "00652423",
            "lastpage": "216",
            "pmid": "15521192",
            "pub_year": 2004,
            "title": "Organophosphates{plus 45 degree rule}Nerve Agent Poisoning: Mechanism of Action, Diagnosis, Prophylaxis, And Treatment",
            "volume": "38"
        },
        "bb0025": null,
        "bb0030": {
            "authors": [
                {
                    "first": "Jir\u00ed",
                    "initial": "J.",
                    "last": "Bajgar"
                }
            ],
            "doi": "10.14712/18059694.2016.78",
            "firstpage": "207",
            "issn": "12114286",
            "lastpage": "211",
            "pmid": "21400978",
            "pub_year": 2010,
            "title": "Optimal choice of acetylcholinesterase reactivators for antidotal treatment of nerve agent intoxication.",
            "volume": "53"
        },
        "bb0035": null,
        "bb0040": {
            "authors": [
                {
                    "first": "Ji\u0159\u00ed",
                    "initial": "J.",
                    "last": "Cabal"
                },
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Ku\u010da"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Kassa"
                }
            ],
            "doi": "10.1111/j.1742-7843.2004.950207.x",
            "firstpage": "81",
            "issn": "17427835",
            "lastpage": "86",
            "pmid": "15379785",
            "pub_year": 2004,
            "title": "Specification of the structure of oximes able to reactivate tabun-inhibited acetylcholinesterase",
            "volume": "95"
        },
        "bb0045": {
            "authors": [
                {
                    "first": "C. Linn",
                    "initial": "C.L.",
                    "last": "Cadieux"
                },
                {
                    "first": "Clarence A.",
                    "initial": "C.A.",
                    "last": "Broomfield"
                },
                {
                    "first": "Melanie G.",
                    "initial": "M.G.",
                    "last": "Kirkpatrick"
                },
                {
                    "first": "Meghan E.",
                    "initial": "M.E.",
                    "last": "Kazanski"
                },
                {
                    "first": "David E.",
                    "initial": "D.E.",
                    "last": "Lenz"
                },
                {
                    "first": "Douglas M.",
                    "initial": "D.M.",
                    "last": "Cerasoli"
                }
            ],
            "doi": "10.1016/j.cbi.2010.04.020",
            "firstpage": "229",
            "issn": "00092797",
            "lastpage": "233",
            "pmid": "20433814",
            "pub_year": 2010,
            "title": "Comparison of human and guinea pig acetylcholinesterase sequences and rates of oxime-assisted reactivation",
            "volume": "187"
        },
        "bb0050": {
            "authors": [
                {
                    "first": "Maja",
                    "initial": "M.",
                    "last": "\u010cali\u0107"
                },
                {
                    "first": "Ana Luci\u0107",
                    "initial": "A.L.",
                    "last": "Vrdoljak"
                },
                {
                    "first": "Bo\u017eica",
                    "initial": "B.",
                    "last": "Radi\u0107"
                },
                {
                    "first": "Dubravko",
                    "initial": "D.",
                    "last": "Jeli\u0107"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Jun"
                },
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Ku\u010da"
                },
                {
                    "first": "Zrinka",
                    "initial": "Z.",
                    "last": "Kovarik"
                }
            ],
            "doi": "10.1016/j.tox.2005.11.003",
            "firstpage": "85",
            "issn": "0300483X",
            "lastpage": "96",
            "pmid": "16332406",
            "pub_year": 2006,
            "title": "In vitro and in vivo evaluation of pyridinium oximes: Mode of interaction with acetylcholinesterase, effect on tabun- and soman-poisoned mice and their cytotoxicity",
            "volume": "219"
        },
        "bb0055": {
            "authors": [
                {
                    "first": "A. F.",
                    "initial": "A.F.",
                    "last": "CHILDS"
                },
                {
                    "first": "D. R.",
                    "initial": "D.R.",
                    "last": "DAVIES"
                },
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "GREEN"
                },
                {
                    "first": "J. P.",
                    "initial": "J.P.",
                    "last": "RUTLAND"
                }
            ],
            "doi": "10.1111/j.1476-5381.1955.tb00106.x",
            "firstpage": "462",
            "issn": "03660826",
            "lastpage": "465",
            "pmid": "13276605",
            "pub_year": 1955,
            "title": "The reactivation by oximes and hydroxamic acids of cholinesterase inhibited by organo-phosphorus compounds",
            "volume": "10"
        },
        "bb0060": {
            "authors": [
                {
                    "first": "John G.",
                    "initial": "J.G.",
                    "last": "Clement"
                },
                {
                    "first": "Arnold S.",
                    "initial": "A.S.",
                    "last": "Hansen"
                },
                {
                    "first": "Camille A.",
                    "initial": "C.A.",
                    "last": "Boulet"
                }
            ],
            "doi": "10.1007/BF01974018",
            "firstpage": "216",
            "issn": "03405761",
            "lastpage": "219",
            "pmid": "1497487",
            "pub_year": 1992,
            "title": "Efficacy of HL\u00f6-7 and pyrimidoxime as antidotes of nerve agent poisoning in mice",
            "volume": "66"
        },
        "bb0065": {
            "authors": [
                {
                    "first": "R. M.",
                    "initial": "R.M.",
                    "last": "Dawson"
                }
            ],
            "doi": "10.1002/jat.2550140502",
            "firstpage": "317",
            "issn": "0260437X",
            "lastpage": "331",
            "pmid": "7822680",
            "pub_year": 1994,
            "title": "Review of oximes available for treatment of nerve agent poisoning",
            "volume": "14"
        },
        "bb0070": {
            "authors": [
                {
                    "first": "Reinaldo T.",
                    "initial": "R.T.",
                    "last": "Delfino"
                },
                {
                    "first": "Tatiana S.",
                    "initial": "T.S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Jos\u00e9 D.",
                    "initial": "J.D.",
                    "last": "Figueroa-Villar"
                }
            ],
            "doi": "10.1590/S0103-50532009000300003",
            "firstpage": "407",
            "issn": "01035053",
            "lastpage": "428",
            "pub_year": 2009,
            "title": "Organophosphorus compounds as chemical warfare agents: A review",
            "volume": "20"
        },
        "bb0075": {
            "authors": [
                {
                    "first": "Elie",
                    "initial": "E.",
                    "last": "Dolgin"
                }
            ],
            "doi": "10.1038/nm1013-1194",
            "firstpage": "1194",
            "issn": "10788956",
            "lastpage": "1195",
            "pmid": "24100968",
            "pub_year": 2013,
            "title": "Syrian gas attack reinforces need for better anti-sarin drugs",
            "volume": "19"
        },
        "bb0080": {
            "authors": [
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "DULTZ"
                },
                {
                    "first": "M. A.",
                    "initial": "M.A.",
                    "last": "EPSTEIN"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "FREEMAN"
                },
                {
                    "first": "E. H.",
                    "initial": "E.H.",
                    "last": "GRAY"
                },
                {
                    "first": "W. B.",
                    "initial": "W.B.",
                    "last": "WEIL"
                }
            ],
            "firstpage": "522",
            "issn": "00223565",
            "lastpage": "531",
            "pmid": "13429460",
            "pub_year": 1957,
            "title": "Studies on a group of oximes as therapeutic compounds in sarin poisoning.",
            "volume": "119"
        },
        "bb0085": {
            "authors": [
                {
                    "first": "Fredrik",
                    "initial": "F.",
                    "last": "Ekstr\u00f6m"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "H\u00f6rnberg"
                },
                {
                    "first": "Elisabet",
                    "initial": "E.",
                    "last": "Artursson"
                },
                {
                    "first": "Lars Gunnar",
                    "initial": "L.G.",
                    "last": "Hammarstr\u00f6m"
                },
                {
                    "first": "Gunter",
                    "initial": "G.",
                    "last": "Schneider"
                },
                {
                    "first": "Yuan Ping",
                    "initial": "Y.P.",
                    "last": "Pang"
                }
            ],
            "doi": "10.1371/journal.pone.0005957",
            "issn": "19326203",
            "pmid": "19536291",
            "pub_year": 2009,
            "title": "Structure of HI-6-sarin-acetylcholinesterase determined by x-ray crystallography and molecular dynamics simulation: Reactivator mechanism and design",
            "volume": "4"
        },
        "bb0090": {
            "authors": [
                {
                    "first": "George L.",
                    "initial": "G.L.",
                    "last": "Ellman"
                },
                {
                    "first": "K. Diane",
                    "initial": "K.D.",
                    "last": "Courtney"
                },
                {
                    "first": "Valentino",
                    "initial": "V.",
                    "last": "Andres"
                },
                {
                    "first": "Robert M.",
                    "initial": "R.M.",
                    "last": "Featherstone"
                }
            ],
            "firstpage": "88",
            "issn": "00062952",
            "lastpage": "IN2",
            "pmid": "13726518",
            "pub_year": 1961,
            "title": "A new and rapid colorimetric determination of acetylcholinesterase activity",
            "volume": "7"
        },
        "bb0095": {
            "authors": [
                {
                    "first": "Emilio Xavier",
                    "initial": "E.X.",
                    "last": "Esposito"
                },
                {
                    "first": "Terry R.",
                    "initial": "T.R.",
                    "last": "Stouch"
                },
                {
                    "first": "Troy",
                    "initial": "T.",
                    "last": "Wymore"
                },
                {
                    "first": "Jeffry D.",
                    "initial": "J.D.",
                    "last": "Madura"
                }
            ],
            "doi": "10.1021/tx400350b",
            "firstpage": "99",
            "issn": "0893228X",
            "lastpage": "110",
            "pmid": "24443939",
            "pub_year": 2014,
            "title": "Exploring the physicochemical properties of oxime-reactivation therapeutics for cyclosarin, sarin, tabun, and VX inactivated acetylcholinesterase",
            "volume": "27"
        },
        "bb0100": {
            "authors": [
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Eyer"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Hagedorn"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Klimmek"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Lippstreu"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "L\u00f6ffler"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Oldiges"
                },
                {
                    "first": "U.",
                    "initial": "U.",
                    "last": "Sp\u00f6hrer"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Steidl"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Szinicz"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Worek"
                }
            ],
            "doi": "10.1007/BF01981499",
            "firstpage": "603",
            "issn": "03405761",
            "lastpage": "621",
            "pmid": "1482283",
            "pub_year": 1992,
            "title": "HL\u00f6 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases",
            "volume": "66"
        },
        "bb0105": {
            "authors": [
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Eyer"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Radtke"
                },
                {
                    "first": "Franz",
                    "initial": "F.",
                    "last": "Worek"
                }
            ],
            "doi": "10.1016/j.bcp.2008.02.021",
            "firstpage": "2045",
            "issn": "00062952",
            "lastpage": "2053",
            "pmid": "18384757",
            "pub_year": 2008,
            "title": "Reactions of isodimethoate with human red cell acetylcholinesterase",
            "volume": "75"
        },
        "bb0110": {
            "authors": [
                {
                    "first": "Joseph H.",
                    "initial": "J.H.",
                    "last": "Fleisher"
                },
                {
                    "first": "Larrel W.",
                    "initial": "L.W.",
                    "last": "Harris"
                },
                {
                    "first": "Gail R.",
                    "initial": "G.R.",
                    "last": "Miller"
                },
                {
                    "first": "Norman C.",
                    "initial": "N.C.",
                    "last": "Thomas"
                },
                {
                    "first": "William J.",
                    "initial": "W.J.",
                    "last": "Cliff"
                }
            ],
            "doi": "10.1016/0041-008X(70)90160-2",
            "firstpage": "40",
            "issn": "0041008X",
            "lastpage": "47",
            "pmid": "5416754",
            "pub_year": 1970,
            "title": "Antagonism of sarin poisoning in rats and guinea pigs by atropine, oximes, and mecamylamine",
            "volume": "16"
        },
        "bb0120": null,
        "bb0125": {
            "authors": [
                {
                    "first": "ROBERT H.",
                    "initial": "R.H.",
                    "last": "INNS"
                },
                {
                    "first": "LEVENCE",
                    "initial": "L.",
                    "last": "LEADBEATER"
                }
            ],
            "doi": "10.1111/j.2042-7158.1983.tb04316.x",
            "firstpage": "427",
            "issn": "00223573",
            "lastpage": "433",
            "pmid": "6136583",
            "pub_year": 1983,
            "title": "The efficacy of bispyridinium derivatives in the treatment of organophosphonate poisoning in the guinea\u2010pig",
            "volume": "35"
        },
        "bb0135": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Kassa"
                }
            ],
            "doi": "10.1191/096032798678908855",
            "firstpage": "331",
            "issn": "09603271",
            "lastpage": "335",
            "pmid": "9688357",
            "pub_year": 1998,
            "title": "A comparison of the efficacy of new asymmetric bispyridinium oxime BI-6 with other oximes (obidoxime, HI-6) against soman in rats",
            "volume": "17"
        },
        "bb0140": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Kassa"
                }
            ],
            "doi": "10.1081/CLT-120015840",
            "firstpage": "803",
            "issn": "07313810",
            "lastpage": "816",
            "pmid": "12475193",
            "pub_year": 2002,
            "title": "Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents",
            "volume": "40"
        },
        "bb0145": {
            "authors": [
                {
                    "first": "Jir\u00ed",
                    "initial": "J.",
                    "last": "Kassa"
                }
            ],
            "firstpage": "87",
            "issn": "12114286",
            "lastpage": "90",
            "pmid": "16259318",
            "pub_year": 2005,
            "title": "The influence of the time of antidotal treatment administration on the potency of newly developed oximes to counteract acute toxic effects of tabun in mice.",
            "volume": "48"
        },
        "bb0150": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Koiplovitz"
                },
                {
                    "first": "L. W.",
                    "initial": "L.W.",
                    "last": "Harris"
                },
                {
                    "first": "D. R.",
                    "initial": "D.R.",
                    "last": "Anderson"
                },
                {
                    "first": "W. J.",
                    "initial": "W.J.",
                    "last": "Lennox"
                },
                {
                    "first": "J. R.",
                    "initial": "J.R.",
                    "last": "Stewart"
                }
            ],
            "doi": "10.1093/toxsci/18.1.102",
            "firstpage": "102",
            "issn": "10966080",
            "lastpage": "106",
            "pmid": "1601200",
            "pub_year": 1992,
            "title": "Reduction by pyridostigmine pretreatment of the efficacy of atropine and 2-PAM treatment of Sarin and VX poisoning in rodents",
            "volume": "18"
        },
        "bb0155": {
            "authors": [
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Kuca"
                },
                {
                    "first": "Jiri",
                    "initial": "J.",
                    "last": "Cabal"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Jun"
                },
                {
                    "first": "Jiri",
                    "initial": "J.",
                    "last": "Bajgar"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Hrabinova"
                }
            ],
            "doi": "10.1080/14756360600850916",
            "firstpage": "663",
            "issn": "14756366",
            "lastpage": "666",
            "pmid": "17252938",
            "pub_year": 2006,
            "title": "Potency of new structurally different oximes to reactivate cyclosarin-inhibited human brain acetylcholinesterases",
            "volume": "21"
        },
        "bb0160": {
            "authors": [
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Kuca"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Jun"
                },
                {
                    "first": "Jiri",
                    "initial": "J.",
                    "last": "Bajgar"
                }
            ],
            "doi": "10.2174/138161207782360546",
            "firstpage": "3445",
            "issn": "13816128",
            "lastpage": "3452",
            "pmid": "18045198",
            "pub_year": 2007,
            "title": "Structural factors influencing potency of currently used acetylcholinesterase reactivators for treatment of cyclosarin intoxications",
            "volume": "13"
        },
        "bb0165": {
            "authors": [
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Kuca"
                },
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Musilek"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Stodulka"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Marek"
                },
                {
                    "first": "Petra",
                    "initial": "P.",
                    "last": "Hanusova"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Jun"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Hrabinova"
                },
                {
                    "first": "Jiri",
                    "initial": "J.",
                    "last": "Kassa"
                },
                {
                    "first": "Bohuslav",
                    "initial": "B.",
                    "last": "Dolezal"
                }
            ],
            "doi": "10.2174/157018007781788462",
            "firstpage": "510",
            "issn": "15701808",
            "lastpage": "512",
            "pub_year": 2007,
            "title": "Twelve different HI-6 salts and their potency to reactivate cyclosarin inhibited AChE in vitro",
            "volume": "4"
        },
        "bb0170": {
            "authors": [
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Ku\u010da"
                },
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Mus\u00edlek"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Jun"
                },
                {
                    "first": "Miroslav",
                    "initial": "M.",
                    "last": "Pohanka"
                },
                {
                    "first": "Jana \u017dd \u00e1rov\u00e1",
                    "initial": "J.Z.a.",
                    "last": "Karasov\u00e1"
                },
                {
                    "first": "Ladislav",
                    "initial": "L.",
                    "last": "Novotn\u00fd"
                },
                {
                    "first": "Lucie",
                    "initial": "L.",
                    "last": "Musilov\u00e1"
                }
            ],
            "firstpage": "143",
            "issn": "1214021X",
            "lastpage": "149",
            "pub_year": 2009,
            "title": "Could oxime HI-6 really be considered as \"broad-spectrum\" antidote?",
            "volume": "7"
        },
        "bb0175": {
            "authors": [
                {
                    "first": "Paul M.",
                    "initial": "P.M.",
                    "last": "Lundy"
                },
                {
                    "first": "Arnold S.",
                    "initial": "A.S.",
                    "last": "Hansen"
                },
                {
                    "first": "Brian T.",
                    "initial": "B.T.",
                    "last": "Hand"
                },
                {
                    "first": "Camille A.",
                    "initial": "C.A.",
                    "last": "Boulet"
                }
            ],
            "doi": "10.1016/0300-483X(92)90089-W",
            "firstpage": "99",
            "issn": "0300483X",
            "lastpage": "105",
            "pmid": "1539175",
            "pub_year": 1992,
            "title": "Comparison of several oximes against poisining by soman, tabun and GF",
            "volume": "72"
        },
        "bb0180": {
            "authors": [
                {
                    "first": "Paul M.",
                    "initial": "P.M.",
                    "last": "Lundy"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Raveh"
                },
                {
                    "first": "Gabriel",
                    "initial": "G.",
                    "last": "Amitai"
                }
            ],
            "doi": "10.2165/00139709-200625040-00004",
            "firstpage": "231",
            "issn": "11762551",
            "lastpage": "243",
            "pmid": "17288495",
            "pub_year": 2006,
            "title": "Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning.",
            "volume": "25"
        },
        "bb0190": {
            "authors": [
                {
                    "first": "Donald M.",
                    "initial": "D.M.",
                    "last": "Maxwell"
                },
                {
                    "first": "Irwin",
                    "initial": "I.",
                    "last": "Koplovitz"
                },
                {
                    "first": "Franz",
                    "initial": "F.",
                    "last": "Worek"
                },
                {
                    "first": "Richard E.",
                    "initial": "R.E.",
                    "last": "Sweeney"
                }
            ],
            "doi": "10.1016/j.taap.2008.04.007",
            "firstpage": "157",
            "issn": "0041008X",
            "lastpage": "164",
            "pmid": "18508103",
            "pub_year": 2008,
            "title": "A structure-activity analysis of the variation in oxime efficacy against nerve agents",
            "volume": "231"
        },
        "bb0195": null,
        "bb0200": {
            "authors": [
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Musilek"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Kuca"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Jun"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Dohnal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Dolezal"
                }
            ],
            "doi": "10.1080/14756360500179762",
            "firstpage": "409",
            "issn": "14756366",
            "lastpage": "415",
            "pmid": "16335048",
            "pub_year": 2005,
            "title": "Synthesis of a novel series of bispyridinium compounds bearing a xylene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase",
            "volume": "20"
        },
        "bb0205": {
            "authors": [
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Myers"
                }
            ],
            "doi": "10.1016/0006-3002(59)90311-7",
            "firstpage": "555",
            "issn": "00063002",
            "lastpage": "557",
            "pmid": "14425589",
            "pub_year": 1959,
            "title": "Mechanism of the prophylactic action of diacetylmonoxime against sarin poisoning",
            "volume": "34"
        },
        "bb0210": {
            "authors": [
                {
                    "first": "Tetsu",
                    "initial": "T.",
                    "last": "Okumura"
                },
                {
                    "first": "Teruhiko",
                    "initial": "T.",
                    "last": "Hisaoka"
                },
                {
                    "first": "Toshio",
                    "initial": "T.",
                    "last": "Naito"
                },
                {
                    "first": "Hiroshi",
                    "initial": "H.",
                    "last": "Isonuma"
                },
                {
                    "first": "Sumie",
                    "initial": "S.",
                    "last": "Okumura"
                },
                {
                    "first": "Kunihisa",
                    "initial": "K.",
                    "last": "Miura"
                },
                {
                    "first": "Hiroshi",
                    "initial": "H.",
                    "last": "Maekawa"
                },
                {
                    "first": "Shinichi",
                    "initial": "S.",
                    "last": "Ishimatsu"
                },
                {
                    "first": "Nobukatsu",
                    "initial": "N.",
                    "last": "Takasu"
                },
                {
                    "first": "Kouichiro",
                    "initial": "K.",
                    "last": "Suzuki"
                }
            ],
            "doi": "10.1016/j.etap.2004.12.005",
            "firstpage": "447",
            "issn": "13826689",
            "lastpage": "450",
            "pub_year": 2005,
            "title": "Acute and chronic effects of sarin exposure from the Tokyo subway incident",
            "volume": "19"
        },
        "bb0215": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Oldiges"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Schoene"
                }
            ],
            "doi": "10.1007/BF00577721",
            "firstpage": "293",
            "issn": "03405761",
            "lastpage": "305",
            "pmid": "5501176",
            "pub_year": 1970,
            "title": "Antidotal effects of pyridinium- and imidazolium salts on soman and paraoxon poisoning in mice",
            "volume": "26"
        },
        "bb0220": {
            "authors": [
                {
                    "first": "Zoran",
                    "initial": "Z.",
                    "last": "Radi\u0107"
                },
                {
                    "first": "Rakesh K.",
                    "initial": "R.K.",
                    "last": "Sit"
                },
                {
                    "first": "Zrinka",
                    "initial": "Z.",
                    "last": "Kovarik"
                },
                {
                    "first": "Suzana",
                    "initial": "S.",
                    "last": "Berend"
                },
                {
                    "first": "Edzna",
                    "initial": "E.",
                    "last": "Garcia"
                },
                {
                    "first": "Limin",
                    "initial": "L.",
                    "last": "Zhang"
                },
                {
                    "first": "Gabriel",
                    "initial": "G.",
                    "last": "Amitai"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Green"
                },
                {
                    "first": "Bo\u017eica",
                    "initial": "B.",
                    "last": "Radi\u0107"
                },
                {
                    "first": "Valery V.",
                    "initial": "V.V.",
                    "last": "Fokin"
                },
                {
                    "first": "K. Barry",
                    "initial": "K.B.",
                    "last": "Sharpless"
                },
                {
                    "first": "Palmer",
                    "initial": "P.",
                    "last": "Taylor"
                }
            ],
            "doi": "10.1074/jbc.M111.333732",
            "firstpage": "11798",
            "issn": "00219258",
            "lastpage": "11809",
            "pmid": "22343626",
            "pub_year": 2012,
            "title": "Refinement of structural leads for centrally acting oxime reactivators of phosphylated cholinesterases",
            "volume": "287"
        },
        "bb0230": {
            "authors": [
                {
                    "first": "Yossi",
                    "initial": "Y.",
                    "last": "Rosman"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Makarovsky"
                },
                {
                    "first": "Yedidia",
                    "initial": "Y.",
                    "last": "Bentur"
                },
                {
                    "first": "Shai",
                    "initial": "S.",
                    "last": "Shrot"
                },
                {
                    "first": "Tsvika",
                    "initial": "T.",
                    "last": "Dushnistky"
                },
                {
                    "first": "Amir",
                    "initial": "A.",
                    "last": "Krivoy"
                }
            ],
            "doi": "10.1016/j.ajem.2009.01.035",
            "firstpage": "1117",
            "issn": "07356757",
            "lastpage": "1124",
            "pmid": "19931761",
            "pub_year": 2009,
            "title": "Carbamate poisoning: treatment recommendations in the setting of a mass casualties event",
            "volume": "27"
        },
        "bb0235": {
            "authors": [
                {
                    "first": "J. P.",
                    "initial": "J.P.",
                    "last": "RUTLAND"
                }
            ],
            "doi": "10.1111/j.1476-5381.1958.tb00228.x",
            "firstpage": "399",
            "issn": "03660826",
            "lastpage": "403",
            "pmid": "13618543",
            "pub_year": 1958,
            "title": "The effect of some oximes in sarin poisoning",
            "volume": "13"
        },
        "bb0240": {
            "authors": [
                {
                    "first": "Tsung Ming",
                    "initial": "T.M.",
                    "last": "Shih"
                },
                {
                    "first": "Jacob W.",
                    "initial": "J.W.",
                    "last": "Skovira"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "O'Donnell"
                },
                {
                    "first": "John H.",
                    "initial": "J.H.",
                    "last": "McDonough"
                }
            ],
            "doi": "10.1080/15376510903213892",
            "firstpage": "386",
            "issn": "15376516",
            "lastpage": "400",
            "pmid": "19778239",
            "pub_year": 2009,
            "title": "Evaluation of nine oximes on in vivo reactivation of blood, brain, and tissue cholinesterase activity inhibited by organophosphorus nerve agents at lethal dose Reactivation of nerve agent-inhibited AChE by oximes Tsung-Ming Shih et al.",
            "volume": "19"
        },
        "bb0245": {
            "authors": [
                {
                    "first": "Tsung Ming",
                    "initial": "T.M.",
                    "last": "Shih"
                },
                {
                    "first": "Jacob W.",
                    "initial": "J.W.",
                    "last": "Skovira"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "O'Donnell"
                },
                {
                    "first": "John H.",
                    "initial": "J.H.",
                    "last": "McDonough"
                }
            ],
            "doi": "10.1016/j.cbi.2010.03.006",
            "firstpage": "207",
            "issn": "00092797",
            "lastpage": "214",
            "pmid": "20223229",
            "pub_year": 2010,
            "title": "In vivo reactivation by oximes of inhibited blood, brain and peripheral tissue cholinesterase activity following exposure to nerve agents in guinea pigs",
            "volume": "187"
        },
        "bb0250": null,
        "bb0255": {
            "authors": [
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Schoene"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Oldiges"
                }
            ],
            "firstpage": "110",
            "issn": "00039780",
            "lastpage": "123",
            "pmid": "4746622",
            "pub_year": 1973,
            "title": "Efficacy of pyridinium salts in cases of tabun and sarin poisoning in vivo and in vitro",
            "volume": "204"
        },
        "bb0265": {
            "authors": [
                {
                    "first": "Rakesh K.",
                    "initial": "R.K.",
                    "last": "Sit"
                },
                {
                    "first": "Zoran",
                    "initial": "Z.",
                    "last": "Radi\u0107"
                },
                {
                    "first": "Valeria",
                    "initial": "V.",
                    "last": "Gerardi"
                },
                {
                    "first": "Limin",
                    "initial": "L.",
                    "last": "Zhang"
                },
                {
                    "first": "Edzna",
                    "initial": "E.",
                    "last": "Garcia"
                },
                {
                    "first": "Maja",
                    "initial": "M.",
                    "last": "Katalini\u0107"
                },
                {
                    "first": "Gabriel",
                    "initial": "G.",
                    "last": "Amitai"
                },
                {
                    "first": "Zrinka",
                    "initial": "Z.",
                    "last": "Kovarik"
                },
                {
                    "first": "Valery V.",
                    "initial": "V.V.",
                    "last": "Fokin"
                },
                {
                    "first": "K. Barry",
                    "initial": "K.B.",
                    "last": "Sharpless"
                },
                {
                    "first": "Palmer",
                    "initial": "P.",
                    "last": "Taylor"
                }
            ],
            "doi": "10.1074/jbc.M111.230656",
            "firstpage": "19422",
            "issn": "00219258",
            "lastpage": "19430",
            "pmid": "21464125",
            "pub_year": 2011,
            "title": "New structural scaffolds for centrally acting oxime reactivators of phosphylated cholinesterases",
            "volume": "286"
        },
        "bb0270": {
            "authors": [
                {
                    "first": "Jacob W.",
                    "initial": "J.W.",
                    "last": "Skovira"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "O'Donnell"
                },
                {
                    "first": "Irwin",
                    "initial": "I.",
                    "last": "Koplovitz"
                },
                {
                    "first": "Robert K.",
                    "initial": "R.K.",
                    "last": "Kan"
                },
                {
                    "first": "John H.",
                    "initial": "J.H.",
                    "last": "McDonough"
                },
                {
                    "first": "Tsung Ming",
                    "initial": "T.M.",
                    "last": "Shih"
                }
            ],
            "doi": "10.1016/j.cbi.2010.03.010",
            "firstpage": "318",
            "issn": "00092797",
            "lastpage": "324",
            "pmid": "20230808",
            "pub_year": 2010,
            "title": "Reactivation of brain acetylcholinesterase by monoisonitrosoacetone increases the therapeutic efficacy against nerve agents in guinea pigs",
            "volume": "187"
        },
        "bb0275": {
            "authors": [
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Soukup"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Jun"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Tobin"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Kuca"
                }
            ],
            "doi": "10.1007/s00204-012-0977-1",
            "firstpage": "711",
            "issn": "03405761",
            "lastpage": "719",
            "pmid": "23179755",
            "pub_year": 2013,
            "title": "The summary on non-reactivation cholinergic properties of oxime reactivators: The interaction with muscarinic and nicotinic receptors",
            "volume": "87"
        },
        "bb0280": {
            "authors": [
                {
                    "first": "Milo\u0161 P.",
                    "initial": "M.P.",
                    "last": "Stojiljkovi\u0107"
                },
                {
                    "first": "Milan",
                    "initial": "M.",
                    "last": "Jokanovi\u0107"
                }
            ],
            "firstpage": "435",
            "issn": "00041254",
            "lastpage": "443",
            "pmid": "17265683",
            "pub_year": 2006,
            "title": "Pyridinium oximes: Rationale for their selection as causal antidotes against organophosphate poisonings and current solutions for auto-injectors",
            "volume": "57"
        },
        "bb0285": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Thiermann"
                },
                {
                    "first": "U.",
                    "initial": "U.",
                    "last": "Mast"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Klimmek"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Eyer"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Hibler"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Pfab"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Felgenhauer"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Zilker"
                }
            ],
            "doi": "10.1177/096032719701600809",
            "firstpage": "473",
            "issn": "09603271",
            "lastpage": "480",
            "pmid": "9292288",
            "pub_year": 1997,
            "title": "Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients",
            "volume": "16"
        },
        "bb0290": {
            "authors": [
                {
                    "first": "Horst",
                    "initial": "H.",
                    "last": "Thiermann"
                },
                {
                    "first": "Franz",
                    "initial": "F.",
                    "last": "Worek"
                },
                {
                    "first": "Kai",
                    "initial": "K.",
                    "last": "Kehe"
                }
            ],
            "doi": "10.1016/j.cbi.2013.09.015",
            "firstpage": "435",
            "issn": "00092797",
            "lastpage": "443",
            "pmid": "24091052",
            "pub_year": 2013,
            "title": "Limitations and challenges in treatment of acute chemical warfare agent poisoning",
            "volume": "206"
        },
        "bb0295": null,
        "bb0300": null,
        "bb0305": {
            "authors": [
                {
                    "first": "Victor",
                    "initial": "V.",
                    "last": "Voicu"
                },
                {
                    "first": "Flavian \u015etefan",
                    "initial": "F.S.",
                    "last": "R\u01cedulescu"
                },
                {
                    "first": "Andrei",
                    "initial": "A.",
                    "last": "Medvedovici"
                }
            ],
            "doi": "10.1517/17425255.2013.736489",
            "firstpage": "31",
            "issn": "17425255",
            "lastpage": "50",
            "pmid": "23176543",
            "pub_year": 2013,
            "title": "Toxicological considerations of acetylcholinesterase reactivators",
            "volume": "9"
        },
        "bb0310": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Wille"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Kaltenbach"
                },
                {
                    "first": "Horst",
                    "initial": "H.",
                    "last": "Thiermann"
                },
                {
                    "first": "Franz",
                    "initial": "F.",
                    "last": "Worek"
                }
            ],
            "doi": "10.1016/j.cbi.2013.08.004",
            "firstpage": "569",
            "issn": "00092797",
            "lastpage": "572",
            "pmid": "23962483",
            "pub_year": 2013,
            "title": "Investigation of kinetic interactions between approved oximes and human acetylcholinesterase inhibited by pesticide carbamates",
            "volume": "206"
        },
        "bb0315": {
            "authors": [
                {
                    "first": "Franz",
                    "initial": "F.",
                    "last": "Worek"
                },
                {
                    "first": "Horst",
                    "initial": "H.",
                    "last": "Thiermann"
                },
                {
                    "first": "Ladislaus",
                    "initial": "L.",
                    "last": "Szinicz"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Eyer"
                }
            ],
            "doi": "10.1016/j.bcp.2004.07.038",
            "firstpage": "2237",
            "issn": "00062952",
            "lastpage": "2248",
            "pmid": "15498514",
            "pub_year": 2004,
            "title": "Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes",
            "volume": "68"
        },
        "bb0320": {
            "authors": [
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Worek"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Eyer"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Aurbek"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Szinicz"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Thiermann"
                }
            ],
            "doi": "10.1016/j.taap.2006.10.001",
            "firstpage": "226",
            "issn": "0041008X",
            "lastpage": "234",
            "pmid": "17112559",
            "pub_year": 2007,
            "title": "Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis",
            "volume": "219"
        },
        "bb0325": {
            "authors": [
                {
                    "first": "Franz",
                    "initial": "F.",
                    "last": "Worek"
                },
                {
                    "first": "Horst",
                    "initial": "H.",
                    "last": "Thiermann"
                }
            ],
            "doi": "10.1016/j.pharmthera.2013.04.009",
            "firstpage": "249",
            "issn": "01637258",
            "lastpage": "259",
            "pmid": "23603539",
            "pub_year": 2013,
            "title": "The value of novel oximes for treatment of poisoning by organophosphorus compounds",
            "volume": "139"
        },
        "bb0330": null
    },
    "body_text": [
        {
            "endOffset": 42644,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Both provided significant ChE reactivation and MMB4 DMS animals were asymptomatic at the 24 hour observation.",
            "startOffset": 42535,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 51187,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bb0320": {
                    "endOffset": 51084,
                    "startOffset": 51066
                }
            },
            "secId": "s0100",
            "sentence": "Obidoxime Cl2 has been shown to be one of the most efficacious reactivators against OP pesticides by other laboratories (Worek et al., 2007), and, in the present study, the oxime performed well against the nerve agents GA, GB, and VX as well.",
            "startOffset": 50945,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 28216,
            "parents": [],
            "refoffsets": {
                "bb0085": {
                    "endOffset": 28214,
                    "startOffset": 28175
                },
                "bb0155": {
                    "endOffset": 28214,
                    "startOffset": 28175
                }
            },
            "secId": "s0005",
            "sentence": "The structural differences among HL\u00f6-7, HI-6, and obidoxime are in the number and position(s) of aldoximes on the pyridine rings (Kuca et al., 2006; Ekstr\u00f6m et al., 2009).",
            "startOffset": 28045,
            "title": "Introduction"
        },
        {
            "endOffset": 47771,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "HI-6 DMS and TMB-4 also provided significant protection against paraoxon with 13% and 25% lethality, respectively.",
            "startOffset": 47657,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 46115,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Animal groups treated with those oximes had statistically significant reactivation of AChE compared to the control group animals (Table 7).",
            "startOffset": 45976,
            "title": "VX"
        },
        {
            "endOffset": 47656,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "When treated with 2-PAM Cl, HL\u00f6-7 DMS, obidoxime Cl2, or MMB4 DMS, the lethality for the pesticides paraoxon and phorate oxon were significantly reduced to rates between 0 and 25%.",
            "startOffset": 47476,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 43644,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "2-PAM Cl, MMB4 DMS, HI-6 DMS, and TMB-4 significantly mitigated both AChE and BChE inhibition.",
            "startOffset": 43550,
            "title": "Sarin (GB)"
        },
        {
            "endOffset": 40077,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "Fisher's exact tests at a one-sided \u03b1 = 0.05 decision level were used to contrast lethality between control and each treatment group.",
            "startOffset": 39944,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 54266,
            "parents": [],
            "refoffsets": {
                "bb0320": {
                    "endOffset": 54230,
                    "startOffset": 54212
                }
            },
            "secId": "s0020",
            "sentence": "In vitro reactivation studies using human AChE indicated that 2-PAM Cl was generally the least effective against GA, GB, GF, and VX relative to HL\u00f6-7, HI-6, MMB4, and obidoxime (Worek et al., 2007) when compared to the other oximes.",
            "startOffset": 54034,
            "title": "Discussion"
        },
        {
            "endOffset": 27797,
            "parents": [],
            "refoffsets": {
                "bb0220": {
                    "endOffset": 27795,
                    "startOffset": 27777
                }
            },
            "secId": "s0005",
            "sentence": "RS194B (MW = 213.3 Da) and has been shown to reactivate human AChE in vitro and protect mice against VX, GB, and paraoxon (Radi\u0107 et al., 2012).",
            "startOffset": 27654,
            "title": "Introduction"
        },
        {
            "endOffset": 39667,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "For any time period in which the animal was still alive to include moribund, the highest score that an animal could attain was 11.",
            "startOffset": 39537,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 25750,
            "parents": [],
            "secId": "s0005",
            "sentence": "As the only true antidote, i.e., one that reactivates the target molecule AChE, a better oxime therapy would improve the nation's medical response capabilities.",
            "startOffset": 25590,
            "title": "Introduction"
        },
        {
            "endOffset": 25589,
            "parents": [],
            "secId": "s0005",
            "sentence": "Consequently, more effective oxime therapies, including a broader spectrum of activity and/or the capacity to cross the BBB, are being investigated to identify a more effective treatment than 2-PAM Cl.",
            "startOffset": 25388,
            "title": "Introduction"
        },
        {
            "endOffset": 45496,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The LD85 of VX used in this study was based on a dose/lethality probit curve with a slope of 34 (p = 0.041), determined in preparation for this work (data not shown).",
            "startOffset": 45330,
            "title": "VX"
        },
        {
            "endOffset": 45750,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Treatment with those oximes, as well as treatment with obidoxime Cl2, resulted in QOL scores at the minimal \u201cimpaired\u201d level (i.e., ataxia) at the 24 hour observation time point.",
            "startOffset": 45572,
            "title": "VX"
        },
        {
            "endOffset": 39536,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "Moderate and severe signs were scored individually and not as a group.",
            "startOffset": 39466,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 57991,
            "parents": [],
            "secId": "s0020",
            "sentence": "MINA was the only non-heterocyclic oxime tested in the present study.",
            "startOffset": 57922,
            "title": "Discussion"
        },
        {
            "endOffset": 47445,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Although 2-PAM Cl appeared to improve ChE activities, statistical significance could not be determined.",
            "startOffset": 47342,
            "title": "Chlorpyrifos oxon (CPO)"
        },
        {
            "endOffset": 49401,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Fig. 5 collates the complement of the equimolar relative AChE activity at 24 h (100 \u2212 RAAChE = relative AChE inhibition) in order to represent effective oximes with short bars, as in Figs. 3 and 4.",
            "startOffset": 49204,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 24986,
            "parents": [],
            "secId": "s0005",
            "sentence": "Unfortunately, when OP pesticides are included as potential intoxicants, the spectrum of therapeutic effectiveness is even less.",
            "startOffset": 24858,
            "title": "Introduction"
        },
        {
            "endOffset": 49471,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "A similar plot for the equimolar 24-hour BChE is presented in Fig. 6.",
            "startOffset": 49402,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 30843,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s1030",
            "sentence": "The purity values of the CWNAs were > 98.5% as determined by gas chromatography.",
            "startOffset": 30763,
            "title": "Organophosphorus compounds"
        },
        {
            "endOffset": 38389,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "refoffsets": {
                "bb0195": {
                    "endOffset": 38387,
                    "startOffset": 38367
                }
            },
            "secId": "s0050",
            "sentence": "Terminal blood samples were collected and processed for all survivors using Hemoglobind\u2122 (McGarry et al., 2013).",
            "startOffset": 38277,
            "title": "OP challenges and oxime therapies"
        },
        {
            "endOffset": 31849,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0035",
            "sentence": "2-PAM Cl (pralidoxime chloride, 2-hydroxyiminomethyl-1-methylpyridinium chloride; supplied as an injectable drug at 100 mg/mL) and MMB4 DMS (methoxime dimethanesulfonate; 1,1-methylene bis[4(hydroxyimino) methyl]pyridinium) dimethanesulfonate; purity 100%) were supplied by the U.S. Department of Defense.",
            "startOffset": 31544,
            "title": "Oximes"
        },
        {
            "endOffset": 38276,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0050",
            "sentence": "Clinical observations were recorded for 24 h post challenge by individuals not involved in challenges.",
            "startOffset": 38174,
            "title": "OP challenges and oxime therapies"
        },
        {
            "endOffset": 48582,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "There was no significant difference in cholinesterase activity of survivors within the phorate oxon-challenged animals at 24 h.",
            "startOffset": 48455,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 32348,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0035",
            "sentence": "HI-6 DMS (4-carbamoyl-1-[({2-[(E)-(hydroxyimino)methyl)]pyridinium-1-yl}methoxyl)methyl] pyridinium dimesylate; purity 98.7%), MINA ((1E)-1-(hydroxyimino)propan-2-one; purity 98.7%), TMB-4 (trimedoxime bromide; 1\u2032-propane-1,3-diylbis{4-[(E)-(hydroxyimino)methyl]pyridinium} dibromide; purity 98.5%), and HL\u00f6-7 DMS (pyridinium,1-(((4-(aminocarbonyl) pyridinio)methoxy)methyl)-2,4-bis((hydroxyimino)methyl), dimesylate; purity 96.73%) were procured from Southwest Research Institute, San Antonio, TX.",
            "startOffset": 31850,
            "title": "Oximes"
        },
        {
            "endOffset": 35037,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0045",
            "sentence": "Body weights, used to determine challenge doses and treatment volumes, were taken the day prior to challenge.",
            "startOffset": 34928,
            "title": "Preparation of animals"
        },
        {
            "endOffset": 25387,
            "parents": [],
            "refoffsets": {
                "bb0250": {
                    "endOffset": 25385,
                    "startOffset": 25348
                },
                "bb0305": {
                    "endOffset": 25385,
                    "startOffset": 25348
                }
            },
            "secId": "s0005",
            "sentence": "As such, they are capable of reactivating cholinesterases (ChEs) in peripheral tissues, but not in the central nervous system (CNS) because they do not readily cross the blood brain barrier (BBB) (Voicu et al., 2013; Shih et al., 2012).",
            "startOffset": 25151,
            "title": "Introduction"
        },
        {
            "endOffset": 39868,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "The lower the animal's QOL score, the closer its exhibited behavior was to that prior to challenge.",
            "startOffset": 39769,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 40592,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Target LD85 challenges successfully produced lethality between 73% and 100% for all OPs except VX.",
            "startOffset": 40494,
            "title": "Effects of OPs at LD85 challenges in positive control animals"
        },
        {
            "endOffset": 24629,
            "parents": [],
            "secId": "s0005",
            "sentence": "The DuoDote\u00ae is a two-chambered, self-propelled syringe used for the intramuscular (IM) injection of atropine (2.1 mg free base) and 2-PAM Cl (600 mg) through the same needle.",
            "startOffset": 24454,
            "title": "Introduction"
        },
        {
            "endOffset": 55692,
            "parents": [],
            "refoffsets": {
                "bb0095": {
                    "endOffset": 55533,
                    "startOffset": 55512
                },
                "bb0165": {
                    "endOffset": 55690,
                    "startOffset": 55672
                }
            },
            "secId": "s0020",
            "sentence": "The dichloride form of HI-6 is moderately effective in vitro at reactivating GB-inhibited rat AChE (Esposito et al., 2014), whereas the dimethanesulfonate salt was shown to be superior in terms of both solubility in biocompatible vehicles and biodistribution (Kuca et al., 2007b).",
            "startOffset": 55412,
            "title": "Discussion"
        },
        {
            "endOffset": 28618,
            "parents": [],
            "refoffsets": {
                "bb0315": {
                    "endOffset": 28616,
                    "startOffset": 28598
                }
            },
            "secId": "s0005",
            "sentence": "HL\u00f6-7 and obidoxime are the most potent reactivators of phosphonylated and phosphorylated AChE, respectively (Worek et al., 2004).",
            "startOffset": 28488,
            "title": "Introduction"
        },
        {
            "endOffset": 53174,
            "parents": [],
            "secId": "s0020",
            "sentence": "It is important to note that since these historical data have been obtained under vastly different experimental conditions, e.g., different animal species, doses, timing and routes of administration of the oxime, adjuvants, or challenge materials, the results may not be directly comparable.",
            "startOffset": 52883,
            "title": "Discussion"
        },
        {
            "endOffset": 58308,
            "parents": [],
            "secId": "s0020",
            "sentence": "However, at the TI dose level (74 \u03bcmol/kg) significant protection was seen with complete survival against both GB and VX.",
            "startOffset": 58187,
            "title": "Discussion"
        },
        {
            "endOffset": 59683,
            "parents": [],
            "secId": "s0025",
            "sentence": "2-PAM chloride, obidoxime dichloride, and HI-6 DMS were identified in the second efficacy tier, and RS194B and MINA offered the least general protection in a third efficacy tier.",
            "startOffset": 59505,
            "title": "Conclusion"
        },
        {
            "endOffset": 34847,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "refoffsets": {
                "bb0015": {
                    "endOffset": 34732,
                    "startOffset": 34714
                },
                "bb0045": {
                    "endOffset": 34810,
                    "startOffset": 34790
                }
            },
            "secId": "s0045",
            "sentence": "The guinea pig was selected based on having low levels of plasma carboxylesterase relative to other rodent species, which is more similar to humans (Bahar et al., 2012), similarity of AChE protein sequence to that of humans (Cadieux et al., 2010), affordability, and historical use.",
            "startOffset": 34565,
            "title": "Preparation of animals"
        },
        {
            "endOffset": 48454,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Against paraoxon, MMB4 DMS and TMB-4 provided reactivation of both ChEs, while HL\u00f6-7 DMS reactivated only AChE, relative to control animals.",
            "startOffset": 48314,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 50169,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "MMB4-DMS, HL\u00f6-7 DMS, 2-PAM Cl, and obidoxime Cl2 showed statistically significant protection against lethality (lethality \u2264 38%) against both phorate oxon and CPO-challenged animals.",
            "startOffset": 49987,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 47897,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Control group animals challenged with paraoxon and phorate oxon had lethality of 84% and 97%, respectively (Tables 9 and 10).",
            "startOffset": 47772,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 59337,
            "parents": [],
            "secId": "s0025",
            "sentence": "In terms of overall best efficacy performance based on 24-hour survivability, QOL, and blood cholinesterase levels, using the standardized equimolar (146 \u03bcmol/kg) approach, treatments of the dimethanesulfonate salts of MMB4 and HL\u00f6-7 offered the most protection.",
            "startOffset": 59075,
            "title": "Conclusion"
        },
        {
            "endOffset": 55345,
            "parents": [],
            "refoffsets": {
                "bb0060": {
                    "endOffset": 55343,
                    "startOffset": 55323
                }
            },
            "secId": "s0020",
            "sentence": "Even prophylactically, HL\u00f6-7 diiodide at 43 \u03bcmol/kg by intraperitoneal injection (IP) was effective for reactivating diaphragm ChE inhibition by the G agents in atropinized mice (Clement et al., 1992).",
            "startOffset": 55144,
            "title": "Discussion"
        },
        {
            "endOffset": 44176,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "It may be of interest that HL\u00f6-7 DMS delayed the time to onset of signs by 25 min, although none of the animals in this group survived to the 24 hour post challenge time point.",
            "startOffset": 44000,
            "title": "Soman (GD)"
        },
        {
            "endOffset": 38887,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0050",
            "sentence": "Cholinesterase activity was normalized to the individual animal's baseline to determine RAAChE and RABChE, which were compared using t-tests.",
            "startOffset": 38746,
            "title": "OP challenges and oxime therapies"
        },
        {
            "endOffset": 54860,
            "parents": [],
            "secId": "s0020",
            "sentence": "In terms of reactivation of blood AChE and BChE 24-hour post-challenge, MMB4 DMS was superior to the other seven oximes tested.",
            "startOffset": 54733,
            "title": "Discussion"
        },
        {
            "endOffset": 30657,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s1030",
            "sentence": "The five CWNAs evaluated were tabun (GA; O-ethyl N,N-dimethyl phosphoramidocyanidate), sarin (GB; O-isopropyl methylphosphonofluoridate), soman (GD; O-pinacolyl methylphosphonofluoridate), cyclosarin (GF, cyclohexyl methylphosphonofluoridate), and VX (O-ethyl S-(2-diisopropylaminoethyl) methylphosphonothiolate).",
            "startOffset": 30344,
            "title": "Organophosphorus compounds"
        },
        {
            "endOffset": 33207,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0035",
            "sentence": "This brought the sodium chloride concentration in the RS194B solution to 1.6%, w/v.",
            "startOffset": 33124,
            "title": "Oximes"
        },
        {
            "endOffset": 33650,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0040",
            "sentence": "Additionally, OP pesticides and oxime analysis was performed by high performance liquid chromatography (HPLC) using an Agilent 1200 series LC and ultraviolet (UV) detector to confirm solution concentration.",
            "startOffset": 33444,
            "title": "Chemical analysis"
        },
        {
            "endOffset": 40908,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Significant oxime-related effects (p < 0.05) are indicated with an asterisk.",
            "startOffset": 40832,
            "title": "Mitigation of the effects of OPs at LD85 challenges by oxime therapies"
        },
        {
            "endOffset": 49727,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "There was a clear division of oxime efficacy in animals challenged with tabun (GA), cyclosarin (GF), and phorate oxon (PHO).",
            "startOffset": 49603,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 51518,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "The 24 hour average QOL score was \u2264 3.0 for MMB4 DMS and \u2264 5.4 for HL\u00f6-7 DMS on a 0 to 12 scale, excluding GD data.",
            "startOffset": 51403,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 57093,
            "parents": [],
            "refoffsets": {
                "bb0220": {
                    "endOffset": 57091,
                    "startOffset": 57073
                }
            },
            "secId": "s0020",
            "sentence": "RS194B is a relatively new compound, the most effective among a class of uncharged N-substituted 2-hydroxyiminoacetamido alkylamine compounds tested in mice (Radi\u0107 et al., 2012).",
            "startOffset": 56915,
            "title": "Discussion"
        },
        {
            "endOffset": 45116,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "HI-6 DMS also provided significant reactivation; however those survivors, as well as the HL\u00f6-7 DMS survivors, had QOL scores that reflected moderate to severe signs at the end of the observation period.",
            "startOffset": 44914,
            "title": "Cyclosarin (GF)"
        },
        {
            "endOffset": 24857,
            "parents": [],
            "refoffsets": {
                "bb0290": {
                    "endOffset": 24855,
                    "startOffset": 24806
                },
                "bb0325": {
                    "endOffset": 24855,
                    "startOffset": 24806
                }
            },
            "secId": "s0005",
            "sentence": "Although the current treatment approach does protect against some OP toxicities, this protection does not extend across all OP CWNAs, i.e., it is not a broad-spectrum antidote (Worek and Thiermann, 2013; Thiermann et al., 2013).",
            "startOffset": 24629,
            "title": "Introduction"
        },
        {
            "endOffset": 27321,
            "parents": [],
            "refoffsets": {
                "bb0320": {
                    "endOffset": 27319,
                    "startOffset": 27301
                }
            },
            "secId": "s0005",
            "sentence": "Although there are few studies assessing the efficacies of oximes against OP pesticides, obidoxime Cl2 is currently regarded as the most efficacious against pesticides (Worek et al., 2007).",
            "startOffset": 27132,
            "title": "Introduction"
        },
        {
            "endOffset": 29498,
            "parents": [],
            "secId": "s0005",
            "sentence": "The overall objective of this study was to compare rigorously the efficacy of currently fielded and select promising novel AChE oxime reactivators under strict standardized experimental conditions to enable an accurate and unbiased assessment of their efficacies against OP CWNAs and pesticides.",
            "startOffset": 29203,
            "title": "Introduction"
        },
        {
            "endOffset": 44834,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "MMB4 DMS provided sufficient protection against GF that QOL scores in treatment group animals compared to control group animals were significantly reduced from 30 min post challenge through the 24 hour observation, when signs were mild to moderate in severity.",
            "startOffset": 44574,
            "title": "Cyclosarin (GF)"
        },
        {
            "endOffset": 26452,
            "parents": [],
            "secId": "s0005",
            "sentence": "The few studies to assess comparative efficacy in animals have typically been confined only to oximes within the same chemical class or moiety developed within a particular laboratory, rather than what is currently approved and fielded worldwide.",
            "startOffset": 26206,
            "title": "Introduction"
        },
        {
            "endOffset": 46931,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Additionally, obidoxime Cl2, MMB4 DMS, HL\u00f6-7 DMS, 2-PAM Cl, and RS194B significantly reduced the frequencies of lacrimation, fasciculations, respiratory distress, and prostration.",
            "startOffset": 46752,
            "title": "Chlorpyrifos oxon (CPO)"
        },
        {
            "endOffset": 55411,
            "parents": [],
            "secId": "s0020",
            "sentence": "HI-6 is available both as a dichloride or dimethanesulfonate salt.",
            "startOffset": 55345,
            "title": "Discussion"
        },
        {
            "endOffset": 46511,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Additionally, with the TI dose of MINA, zero lethality was reported with improvement in the QOL score at 24 h.",
            "startOffset": 46401,
            "title": "VX"
        },
        {
            "endOffset": 28917,
            "parents": [],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 28915,
                    "startOffset": 28863
                },
                "bb0255": {
                    "endOffset": 28915,
                    "startOffset": 28863
                }
            },
            "secId": "s0005",
            "sentence": "TMB-4 originated in 1958 and was the first bis-pyridinium oxime to be effective against GA (Schoene and Oldiges, 1973; Inns and Leadbeater, 1983).",
            "startOffset": 28771,
            "title": "Introduction"
        },
        {
            "endOffset": 34927,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0045",
            "sentence": "Animals were quarantined for 3 to 5 days prior to randomization by body weight.",
            "startOffset": 34848,
            "title": "Preparation of animals"
        },
        {
            "endOffset": 39943,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "QOL scores were compared using non parametric Wilcoxon Mann Whitney tests.",
            "startOffset": 39869,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 59802,
            "parents": [],
            "secId": "s0025",
            "sentence": "TMB-4 was tested at 35 \u03bcmol/kg due to its toxicity and offered survival protection between the second and third tiers.",
            "startOffset": 59684,
            "title": "Conclusion"
        },
        {
            "endOffset": 55143,
            "parents": [],
            "refoffsets": {
                "bb0100": {
                    "endOffset": 55141,
                    "startOffset": 55124
                }
            },
            "secId": "s0020",
            "sentence": "These results concur with the literature in that HL\u00f6-7 DMS is a very good candidate for treatment of most OPs (Eyer et al., 1992).",
            "startOffset": 55013,
            "title": "Discussion"
        },
        {
            "endOffset": 42390,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "This activity level for both ChEs was more than 20% higher than the activity level of the GA-challenged control animals.",
            "startOffset": 42270,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 34316,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0040",
            "sentence": "Target dosing concentrations were prepared at 259 mg/mL (equimolar) and 400 mg/mL (TI) for MMB4 DMS, 270 mg/mL (equimolar) and 400 mg/mL (TI) for HI-6 DMS, 50 mg/mL (equimolar) and 100 mg/mL (TI) for MINA, 100 mg/mL (equimolar) and 500 mg/mL (TI) for RS194B, 102 mg/mL 2-PAM Cl, 205 mg/mL obidoxime Cl2, 63 mg/mL TMB-4, and 302 mg/mL HL\u00f6-7 DMS.",
            "startOffset": 33972,
            "title": "Chemical analysis"
        },
        {
            "endOffset": 44437,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "In addition, half of the MMB4 DMS-treated animals became asymptomatic by 24 hour post challenge.",
            "startOffset": 44341,
            "title": "Cyclosarin (GF)"
        },
        {
            "endOffset": 54732,
            "parents": [],
            "refoffsets": {
                "bb0300": {
                    "endOffset": 54730,
                    "startOffset": 54720
                }
            },
            "secId": "s0020",
            "sentence": "In the present study, MMB4 DMS offered significant protection in terms of survivability against all of the OPs at both the equimolar and TI dose levels except GD, likely due to rapid \u201caging\u201d (irreversible dealkylation of an alkoxy chain on the phosphorus atom) of the GD/AChE conjugate (Vale, 2009).",
            "startOffset": 54433,
            "title": "Discussion"
        },
        {
            "endOffset": 45329,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Although VX lethality in controls was only 52%, the model was able to detect significant efficacy and differentiate among the oximes.",
            "startOffset": 45196,
            "title": "VX"
        },
        {
            "endOffset": 41188,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "However, minor differences were observed in lethality and QOL for select agents when treated with a TI dose of MMB4 DMS, HI-6 DMS or MINA.",
            "startOffset": 41050,
            "title": "Mitigation of the effects of OPs at LD85 challenges by oxime therapies"
        },
        {
            "endOffset": 40337,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Clinical signs of cholinesterase intoxication for control OP animals began within 5 min post challenge for all G agents, CPO, and phorate oxon and by 30 min post challenge for VX and paraoxon.",
            "startOffset": 40145,
            "title": "Effects of OPs at LD85 challenges in positive control animals"
        },
        {
            "endOffset": 49986,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Against GA and GF, MMB4-DMS, HL\u00f6-7 DMS, and HI-6 DMS showed statistically significant protection against lethality (lethality \u2264 38%) relative to control animals, while obidoxime Cl2 was statistically significant against lethality (25% lethality) only for GA.",
            "startOffset": 49728,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 48313,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "QOL scores for the animals treated with 2-PAM Cl, HL\u00f6-7 DMS, obidoxime Cl2, or MMB4 DMS were significantly reduced relative to the control animals at 24 h post challenge, with oxime-treated animals showing only impaired to moderate signs.",
            "startOffset": 48075,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 52751,
            "parents": [],
            "refoffsets": {
                "bb0005": {
                    "endOffset": 52749,
                    "startOffset": 52647
                },
                "bb0065": {
                    "endOffset": 52749,
                    "startOffset": 52647
                },
                "bb0280": {
                    "endOffset": 52749,
                    "startOffset": 52647
                },
                "bb0320": {
                    "endOffset": 52749,
                    "startOffset": 52647
                }
            },
            "secId": "s0020",
            "sentence": "Many research articles have discussed the merits of particular reactivator compounds against specific CWNAs, and several review articles have described the history and protective ratios of medical countermeasures to OP intoxication (Dawson, 1994; Stojiljkovi\u0107 and Jokanovi\u0107, 2006; Worek et al., 2007; Antonijevic and Stojiljkovic, 2007).",
            "startOffset": 52414,
            "title": "Discussion"
        },
        {
            "endOffset": 47191,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Obidoxime Cl2, MMB4 DMS, and HL\u00f6-7 DMS treatment significantly improved QOL scores in treatment groups compared to the control group at 24 h post challenge, at which time clinical signs in the treatment groups were limited to the mild and moderate categories.",
            "startOffset": 46932,
            "title": "Chlorpyrifos oxon (CPO)"
        },
        {
            "endOffset": 50330,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "All other oximes (TMB-4, RS194B, and MINA), when used as therapy against GA, GF, CPO, or phorate oxon, demonstrated low efficacy with generally \u2265 50% lethality.",
            "startOffset": 50170,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 58890,
            "parents": [],
            "refoffsets": {
                "bb0270": {
                    "endOffset": 58888,
                    "startOffset": 58868
                }
            },
            "secId": "s0020",
            "sentence": "Protection by MINA was evident when coadministered with atropine and 2-PAM Cl therapies, though this may be related to concurrent reactivation of peripheral and central cholinesterase by 2-PAM Cl and MINA, respectively (Skovira et al., 2010).",
            "startOffset": 58648,
            "title": "Discussion"
        },
        {
            "endOffset": 59870,
            "parents": [],
            "secId": "s0110",
            "sentence": "The authors have no known conflicts of interest.",
            "startOffset": 59822,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 53833,
            "parents": [],
            "secId": "s0020",
            "sentence": "In the present study, 2-PAM Cl offered significant survival protection against LD85 challenges of GB, VX, and the pesticide oxons; however significant AChE reactivation was observed only for GB and VX.",
            "startOffset": 53632,
            "title": "Discussion"
        },
        {
            "endOffset": 53341,
            "parents": [],
            "secId": "s0020",
            "sentence": "It is the result of this variability in procedures that necessitated the evaluation of promising oximes within a single study in a standardized and comparable manner.",
            "startOffset": 53175,
            "title": "Discussion"
        },
        {
            "endOffset": 58186,
            "parents": [],
            "secId": "s0020",
            "sentence": "Here, protection by MINA alone at the equimolar dose did not reach statistical significance against all OPs tested.",
            "startOffset": 58071,
            "title": "Discussion"
        },
        {
            "endOffset": 57725,
            "parents": [],
            "secId": "s0020",
            "sentence": "TMB-4 at 35 \u03bcmol/kg significantly improved survival rates only against LD85 challenge doses of VX and paraoxon, but significant reactivation of blood AChE was observed only against VX, paraoxon, GB, and CPO.",
            "startOffset": 57518,
            "title": "Discussion"
        },
        {
            "endOffset": 42850,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "All GB-challenged animals survived when treated with either MMB4 DMS or 2-PAM Cl, and the effect was significant (p < 0.05) relative to the 73% lethality obtained in the control animals (Table 5).",
            "startOffset": 42654,
            "title": "Sarin (GB)"
        },
        {
            "endOffset": 52145,
            "parents": [],
            "secId": "s0020",
            "sentence": "Oxime efficacy is an amalgamation of somewhat unrelated physicochemical and pharmacologic factors.",
            "startOffset": 52047,
            "title": "Discussion"
        },
        {
            "endOffset": 43094,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Both oximes delayed the time to onset of signs by 25 min and reduced the frequencies of respiratory distress and prostration.",
            "startOffset": 42969,
            "title": "Sarin (GB)"
        },
        {
            "endOffset": 56915,
            "parents": [],
            "refoffsets": {
                "bb0200": {
                    "endOffset": 56854,
                    "startOffset": 56834
                },
                "bb0285": {
                    "endOffset": 56913,
                    "startOffset": 56891
                }
            },
            "secId": "s0020",
            "sentence": "Obidoxime has exhibited ChE reactivation activity against the pesticides chlorpyrifos (Musilek et al., 2005), parathion, and oxydemeton-methyl (Thiermann et al., 1997).",
            "startOffset": 56747,
            "title": "Discussion"
        },
        {
            "endOffset": 49203,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Fig. 4 presents the mean equimolar QOL scores at the 24-hour observation, and is consistent with the efficacy pattern of the lethality data.",
            "startOffset": 49063,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 34564,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0045",
            "sentence": "Male Hartley guinea pigs were purchased from Charles River (Raleigh, NC & Saint-Constant, QC, Canada) and utilized in accordance with protocol specifications approved by the Institutional Animal Care and Use Committee (IACUC).",
            "startOffset": 34338,
            "title": "Preparation of animals"
        },
        {
            "endOffset": 39132,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "QOL scores were calculated with group averages at each time-point.",
            "startOffset": 39066,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 46400,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Both oximes provided adequate therapy for animals to be asymptomatic by the 24 hour observation.",
            "startOffset": 46304,
            "title": "VX"
        },
        {
            "endOffset": 59074,
            "parents": [],
            "secId": "s0025",
            "sentence": "Collectively, the oxime reactivators MMB4 and HL\u00f6-7 were the most efficacious of all the oximes evaluated across the spectrum of eight subcutaneously administered OPs tested.",
            "startOffset": 58900,
            "title": "Conclusion"
        },
        {
            "endOffset": 41908,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "MMB4 DMS and HL\u00f6-7 DMS treatment resulted in QOL scores that were significantly reduced in treatment group animals compared to control group animals from 30 min post challenge through the 24 hour observation.",
            "startOffset": 41700,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 42115,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Although other oximes provided some benefit at various time points, only MMB4 DMS and HL\u00f6-7 DMS treatment limited clinical signs to the mild or moderate classification at the 24 hour observation time point.",
            "startOffset": 41909,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 28044,
            "parents": [],
            "refoffsets": {
                "bb0095": {
                    "endOffset": 27985,
                    "startOffset": 27964
                }
            },
            "secId": "s0005",
            "sentence": "HL\u00f6-7, HI-6, and obidoxime are bis-pyridinium oximes, each containing two charged pyridine rings (requisite in an oxime for optimal reactivation of VX-inhibited AChE; Esposito et al., 2014) joined by a dimethyl ether (\u2212CH2\u2212O\u2212CH2\u2212) linker (Fig. 1).",
            "startOffset": 27797,
            "title": "Introduction"
        },
        {
            "endOffset": 41544,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Additionally, both oximes reduced the occurrence of respiratory distress and prostration, with MMB4 DMS-treated animals primarily exhibiting only ataxia between 1 and 8 h post challenge.",
            "startOffset": 41358,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 32711,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0035",
            "sentence": "Obidoxime Cl2, L\u00fcH-6 (oxo-[[1-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxymethyl]pyridin-4-ylidene]methyl]azanium dichloride; purity 97.1%) was procured from Sigma Aldrich.",
            "startOffset": 32534,
            "title": "Oximes"
        },
        {
            "endOffset": 28770,
            "parents": [],
            "secId": "s0005",
            "sentence": "MMB4 and TMB-4 are the same 4-position bis-pyridinium aldoxime, except that MMB4 has a -CH2- linker while TMB-4 (a dibromide salt) has a -C3H6- linker.",
            "startOffset": 28619,
            "title": "Introduction"
        },
        {
            "endOffset": 35135,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0045",
            "sentence": "Weights ranged from 250 to 500 g with a mean of 330 g among the 1920 guinea pigs placed on study.",
            "startOffset": 35038,
            "title": "Preparation of animals"
        },
        {
            "endOffset": 24241,
            "parents": [],
            "secId": "s0005",
            "sentence": "The current U.S. therapy regimen includes the administration of atropine in combination with the oxime acetylcholinesterase (AChE) reactivator pralidoxime chloride (2-PAM Cl) (Inchem.org, 1989, 1999), followed by the anticonvulsant diazepam depending on whether convulsive symptoms are observed.",
            "startOffset": 23946,
            "title": "Introduction"
        },
        {
            "endOffset": 42269,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "As shown in Table 4, MMB4 DMS-treated animals exhibited relatively uninhibited activity for both AChE and BChE (greater than 70%) at 24 h post challenge.",
            "startOffset": 42116,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 56006,
            "parents": [],
            "refoffsets": {
                "bb0275": {
                    "endOffset": 56004,
                    "startOffset": 55985
                }
            },
            "secId": "s0020",
            "sentence": "Some have even stated that HI-6, despite poor activity against GA, is as close to a broad-spectrum oxime as any (Soukup et al., 2013).",
            "startOffset": 55872,
            "title": "Discussion"
        },
        {
            "endOffset": 50766,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "In pesticide oxon-challenged animals, MMB4-DMS, HL\u00f6-7 DMS, and obidoxime Cl2 were each significantly efficacious relative to lethality in control animals.",
            "startOffset": 50612,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 57348,
            "parents": [],
            "secId": "s0020",
            "sentence": "However, significant survival was seen against GB and chlorpyrifos oxon at the TI dose level (281 \u03bcmol/kg).",
            "startOffset": 57241,
            "title": "Discussion"
        },
        {
            "endOffset": 40493,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In all OP control animals, salivation or lacrimation, ataxia, fasciculations, respiratory distress, tremors, and prostration were the most prevalent signs.",
            "startOffset": 40338,
            "title": "Effects of OPs at LD85 challenges in positive control animals"
        },
        {
            "endOffset": 50611,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "For oxime therapy against GB, MMB4-DMS, HL\u00f6-7 DMS, HI-6 DMS, 2-PAM Cl, and RS194B all exhibited statistically significant improvement in lethality relative to the controls.",
            "startOffset": 50439,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 51285,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "MMB4 DMS and HL\u00f6-7 DMS were the two most consistently efficacious oximes across all challenge OPs.",
            "startOffset": 51187,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 46303,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "All animals treated with 2-PAM Cl were normal at every observation, and those treated with MMB4 DMS exhibited reduced frequencies of fasciculations, respiratory distress, and prostration.",
            "startOffset": 46116,
            "title": "VX"
        },
        {
            "endOffset": 33971,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0040",
            "sentence": "Prior to use on study, each oxime was determined to be stable for the concentrations required on study at both room temperature (25 \u00b0C) and within refrigeration (4 \u00b0C) for 96 h. Chemical verification and concentration analysis of atropine (King Pharmaceuticals, St. Louis, MO, Batch #RP-526-1) were performed using HPLC.",
            "startOffset": 33651,
            "title": "Chemical analysis"
        },
        {
            "endOffset": 43333,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "MMB4 DMS, 2-PAM Cl, and HI-6 DMS provided sufficient protection against GB that QOL scores in treatment group animals compared to control group animals were significantly reduced from 30 min post challenge through the 24 hour observation.",
            "startOffset": 43095,
            "title": "Sarin (GB)"
        },
        {
            "endOffset": 41699,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Although lethality for GA-challenged animals treated with TMB-4 was 100%, the clinical presentations of respiratory distress and prostration were reduced.",
            "startOffset": 41545,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 52882,
            "parents": [],
            "secId": "s0020",
            "sentence": "In the following discussion, we review each of the oximes tested in the present study within the context of those historical data.",
            "startOffset": 52752,
            "title": "Discussion"
        },
        {
            "endOffset": 55871,
            "parents": [],
            "refoffsets": {
                "bb0060": {
                    "endOffset": 55869,
                    "startOffset": 55786
                },
                "bb0095": {
                    "endOffset": 55869,
                    "startOffset": 55786
                },
                "bb0175": {
                    "endOffset": 55869,
                    "startOffset": 55786
                },
                "bb0320": {
                    "endOffset": 55869,
                    "startOffset": 55786
                }
            },
            "secId": "s0020",
            "sentence": "HI-6 historically is a potent in vitro reactivator of GD- and GF- but not GA-inhibited AChE (Lundy et al., 1992; Clement et al., 1992; Worek et al., 2007; Esposito et al., 2014).",
            "startOffset": 55693,
            "title": "Discussion"
        },
        {
            "endOffset": 55012,
            "parents": [],
            "secId": "s0020",
            "sentence": "Similar to MMB4 DMS, HL\u00f6-7 DMS (at 146 \u03bcmol/kg given at 1 min after challenge) was significantly effective against every OP challenge except GD as well.",
            "startOffset": 54860,
            "title": "Discussion"
        },
        {
            "endOffset": 41357,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Treatment of GA-challenged animals with either MMB4 DMS or HL\u00f6-7 DMS reduced lethality to 13%, significantly less than the 86% obtained in the control animals.",
            "startOffset": 41198,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 51669,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Additionally, reactivation of both AChE and BChE was more than 50% with MMB4 DMS for all OP challenges with the exception of chlorpyrifos oxon and GD.",
            "startOffset": 51519,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 27131,
            "parents": [],
            "refoffsets": {
                "bb0005": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0020": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0025": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0030": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0040": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0050": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0070": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0105": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0135": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0140": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0145": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0160": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0170": {
                    "endOffset": 27129,
                    "startOffset": 26917
                },
                "bb0180": {
                    "endOffset": 27129,
                    "startOffset": 26917
                }
            },
            "secId": "s0005",
            "sentence": "The currently fielded oximes 2-PAM Cl (USA, UK, France), obidoxime Cl2 (L\u00fcH-6; Germany, Netherlands), TMB-4 (trimedoxime bromide; Israel), and HI-6 DMS (Canada, Sweden) are efficacious against specific OP CWNAs (Antonijevic and Stojiljkovic, 2007; Bajgar, 2004, 2009, 2010; Cabal et al., 2004; Calic et al., 2006; Delfino et al., 2009; Eyer et al., 2008; Kassa, 1998, 2002, 2005; Kuca et al., 2007a, 2009; Lundy et al., 2006).",
            "startOffset": 26705,
            "title": "Introduction"
        },
        {
            "endOffset": 39205,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "The signs and scores associated with the signs are described in Table 3.",
            "startOffset": 39133,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 56746,
            "parents": [],
            "refoffsets": {
                "bb0095": {
                    "endOffset": 56744,
                    "startOffset": 56723
                }
            },
            "secId": "s0020",
            "sentence": "In vitro tests showed that obidoxime was a relatively poor reactivator of rat GA/AChE and GF/AChE conjugates, was a moderate reactivator against GB, but performed well against VX (Esposito et al., 2014).",
            "startOffset": 56543,
            "title": "Discussion"
        },
        {
            "endOffset": 31538,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s1030",
            "sentence": "GB, GD, GF, and VX were diluted in 0.9% saline; GA and phorate oxon were diluted in multisol (a biocompatible solution of 48.5% water, 40% propylene glycol, 10% ethanol, and 1.5% benzyl alcohol, all v/v); and chlorpyrifos oxon and paraoxon were diluted in ethanol (99.96%), with the dosing solution concentration of each pesticide being limited to that which would allow the total volume of ethanol injected to be no more than 0.06% (v/w) of the body mass.",
            "startOffset": 31082,
            "title": "Organophosphorus compounds"
        },
        {
            "endOffset": 44340,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Treatment of GF-challenged animals with MMB4 DMS significantly reduced lethality to 13% compared to the 89% lethality in the control group (Table 6).",
            "startOffset": 44191,
            "title": "Cyclosarin (GF)"
        },
        {
            "endOffset": 56218,
            "parents": [],
            "secId": "s0020",
            "sentence": "In the present study, HI-6 DMS at 146 \u03bcmol/kg was significantly effective in promoting survival against GA, GB, GF, and paraoxon, but did not possess as broad a spectrum of activity as did MMB4 DMS or HL\u00f6-7 DMS.",
            "startOffset": 56007,
            "title": "Discussion"
        },
        {
            "endOffset": 38745,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0050",
            "sentence": "A similar calculation was made using butyrylthiocholine turnover rates to determine RABChE for each surviving guinea pig.",
            "startOffset": 38624,
            "title": "OP challenges and oxime therapies"
        },
        {
            "endOffset": 47341,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Among the oximes offering significantly improved survivability, only obidoxime Cl2 also provided statistically significant reactivation of both ChEs.",
            "startOffset": 47192,
            "title": "Chlorpyrifos oxon (CPO)"
        },
        {
            "endOffset": 26705,
            "parents": [],
            "secId": "s0005",
            "sentence": "Since those studies are also often conducted under non-standardized experimental conditions and lack other methodological controls to increase scientific rigor, the unintentional introduction of bias remains a possibility when interpreting the results.",
            "startOffset": 26453,
            "title": "Introduction"
        },
        {
            "endOffset": 32533,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0035",
            "sentence": "RS194B (N-(2-(azepan-1-yl)ethyl)-2-(hydroxyimino)acetamide; purity 96 \u00b1 2%) was procured from Skaggs School of Pharmacy & Pharmaceutical Sciences (University of California, San Diego).",
            "startOffset": 32349,
            "title": "Oximes"
        },
        {
            "endOffset": 39005,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "A QOL scoring system was used to provide an objective value for the clinical signs observed.",
            "startOffset": 38913,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 60046,
            "parents": [],
            "secId": "s0110",
            "sentence": "The views expressed in this article are those of the authors and do not reflect the official policy of the NIH, Department of Health and Human Services, or the U.S. Government.",
            "startOffset": 59870,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 40831,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In Tables 4 through 10, the oxime treatment results for each OP are listed in order of increasing lethality.",
            "startOffset": 40723,
            "title": "Mitigation of the effects of OPs at LD85 challenges by oxime therapies"
        },
        {
            "endOffset": 42534,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Only MMB4 DMS and HI-6 DMS offered greater mitigation of OP effects when the oximes were given at TI-based levels relative to equimolar levels.",
            "startOffset": 42391,
            "title": "Tabun (GA)"
        },
        {
            "endOffset": 49062,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "A comparison with the equimolar (Fig. 2) and TI lethality (Fig. 3) shows that no significant difference is seen in the lethality results for any agents except a slight improvement for GB when treating with MINA.",
            "startOffset": 48851,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 26205,
            "parents": [],
            "refoffsets": {
                "bb0030": {
                    "endOffset": 25918,
                    "startOffset": 25847
                },
                "bb0220": {
                    "endOffset": 25997,
                    "startOffset": 25961
                },
                "bb0240": {
                    "endOffset": 25918,
                    "startOffset": 25847
                },
                "bb0265": {
                    "endOffset": 25997,
                    "startOffset": 25961
                },
                "bb0305": {
                    "endOffset": 25918,
                    "startOffset": 25847
                },
                "bb0320": {
                    "endOffset": 25918,
                    "startOffset": 25847
                }
            },
            "secId": "s0005",
            "sentence": "While many oxime compounds have already been synthesized and tested for broad-spectrum efficacy (Bajgar, 2010; Shih et al., 2009; Voicu et al., 2013; Worek et al., 2007) as well as BBB penetration capabilities (Sit et al., 2011; Radi\u0107 et al., 2012), an actual head-to-head and rigorous comparison of efficacy entailing quality of life (QOL) evaluation after treatment, peripheral blood cholinesterase reactivation, and lethality endpoints has been absent.",
            "startOffset": 25750,
            "title": "Introduction"
        },
        {
            "endOffset": 28487,
            "parents": [],
            "refoffsets": {
                "bb0190": {
                    "endOffset": 28485,
                    "startOffset": 28465
                },
                "bb0215": {
                    "endOffset": 28379,
                    "startOffset": 28354
                }
            },
            "secId": "s0005",
            "sentence": "Also, one of the ring groups in HL\u00f6-7 and HI-6 is an isonicotinamide, which was included in their original synthesis to reduce toxicity (Oldiges and Schoene, 1970) but which, as molecular dynamic studies suggest, may also enhance ChE reactivation (Maxwell et al., 2008).",
            "startOffset": 28217,
            "title": "Introduction"
        },
        {
            "endOffset": 29203,
            "parents": [],
            "refoffsets": {
                "bb0240": {
                    "endOffset": 29201,
                    "startOffset": 29184
                }
            },
            "secId": "s0005",
            "sentence": "The difference between these two similar compounds in terms of toxicity to the Hartley guinea pig by IM injection is remarkable: the 24-hour LD50 (median lethal dose) is 679 mg/kg (1514 \u03bcmol/kg) for MMB4 DMS (unpublished data), and 80 mg/kg (179 \u03bcmol/kg) for TMB-4 (Shih et al., 2009).",
            "startOffset": 28918,
            "title": "Introduction"
        },
        {
            "endOffset": 39768,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "If death was recorded at any time-point, the total score for that period was assigned a value of 12.",
            "startOffset": 39668,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 58539,
            "parents": [],
            "secId": "s0020",
            "sentence": "MINA has been shown to offer significant protection (the lower 95% confidence limits for each PR were > 1) against GB, GF, and VX both with and without atropine therapy, but only at much higher levels (402, 689, and 1148 \u03bcmol/kg).",
            "startOffset": 58309,
            "title": "Discussion"
        },
        {
            "endOffset": 60452,
            "parents": [],
            "secId": "s0110",
            "sentence": "All procedures were conducted in accordance with the principles stated in the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966 (P.L. 89-544), as amended.",
            "startOffset": 60264,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 49603,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "The fact that ChE activity in the blood did not correlate well with lethality can be seen by contrasting Figs. 5 and 6 with Fig. 3.",
            "startOffset": 49472,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 30961,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s1030",
            "sentence": "Chlorpyrifos oxon (purity \u2265 98%) and paraoxon (purity \u2265 98%) were purchased from Chem Service, Inc, West Chester, PA.",
            "startOffset": 30844,
            "title": "Organophosphorus compounds"
        },
        {
            "endOffset": 39065,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "Increasing scores were indicative of a decrease in the QOL.",
            "startOffset": 39006,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 41049,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "It should be noted that no significant decrease in lethality was seen when treating animals with the equimolar dose relative to the TI dose.",
            "startOffset": 40909,
            "title": "Mitigation of the effects of OPs at LD85 challenges by oxime therapies"
        },
        {
            "endOffset": 29755,
            "parents": [],
            "secId": "s0005",
            "sentence": "To accomplish this, the human equivalent FDA-approved dose of 2-PAM Cl was used as the experimental standard and the equimolar oxime therapy was administered to atropinized guinea pigs after an LD85 challenge of each OP CWNA or pesticides (data not shown).",
            "startOffset": 29499,
            "title": "Introduction"
        },
        {
            "endOffset": 52037,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Reactivation of AChE and BChE among survivors with HL\u00f6-7 DMS was not as significant when compared to that of MMB4 DMS; however, both enzymes were reactivated above 30% for all OPs with the exception of chlorpyrifos oxon and GD.",
            "startOffset": 51810,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 56542,
            "parents": [],
            "secId": "s0020",
            "sentence": "Obidoxime dichloride offered significant survival protection against GA, (nearly GB, p = 0.0515), VX, and each of the pesticide oxons, confirming historical data.",
            "startOffset": 56380,
            "title": "Discussion"
        },
        {
            "endOffset": 46751,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Treatment of CPO-challenged animals with obidoxime Cl2, MMB4 DMS, HL\u00f6-7 DMS, and 2-PAM Cl significantly reduced lethality in the treatment group animals to \u2264 38% compared to 78% in the control group animals (Table 8).",
            "startOffset": 46534,
            "title": "Chlorpyrifos oxon (CPO)"
        },
        {
            "endOffset": 35317,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0045",
            "sentence": "Baseline bloods were also collected via the vena cava in chilled K3 EDTA (Covidien, Mansfield, MA) tubes and processed to determine a baseline AChE and BChE activity in whole blood.",
            "startOffset": 35136,
            "title": "Preparation of animals"
        },
        {
            "endOffset": 57240,
            "parents": [],
            "secId": "s0020",
            "sentence": "However, at the equi-molar to 2-PAM Cl level of 146 \u03bcmol/kg, a significant increase in survival was observed only against GB in the present study.",
            "startOffset": 57094,
            "title": "Discussion"
        },
        {
            "endOffset": 44913,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "MMB4 DMS offered statistically significant reactivation of both AChE and BChE.",
            "startOffset": 44835,
            "title": "Cyclosarin (GF)"
        },
        {
            "endOffset": 51402,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "MMB4 DMS treatment resulted in an average 80% survivability while HL\u00f6-7 DMS treatment resulted in an average of 77%.",
            "startOffset": 51286,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 60160,
            "parents": [],
            "secId": "s0110",
            "sentence": "No official support or endorsement of this article by the NIAID, NINDS, or NIH is intended or should be inferred.",
            "startOffset": 60047,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 31081,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s1030",
            "sentence": "Phorate oxon (purity \u2265 97.1%) was synthesized at Battelle's Analytical Chemistry Development Department (Columbus, OH).",
            "startOffset": 30962,
            "title": "Organophosphorus compounds"
        },
        {
            "endOffset": 43549,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Although other oximes provided some statistical significance at various time-points, only MMB4 DMS and 2-PAM Cl treatment resulted in QOL scores at the minimal \u201cimpaired\u201d level at the 24 hour observation time point.",
            "startOffset": 43334,
            "title": "Sarin (GB)"
        },
        {
            "endOffset": 43999,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "When tested against a GD challenge, none of the oximes tested showed any significant differences in the measured endpoints between the treatment and control groups (data not shown).",
            "startOffset": 43818,
            "title": "Soman (GD)"
        },
        {
            "endOffset": 32872,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0035",
            "sentence": "MMB4 DMS, HI-6 DMS, MINA, TMB-4, HL\u00f6-7 DMS, and obidoxime Cl2 were formulated as dosing solutions for intramuscular (IM) injection in normal (0.9%, w/v) saline.",
            "startOffset": 32712,
            "title": "Oximes"
        },
        {
            "endOffset": 45975,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Although the 24 hour QOL scores for both TMB-4 and obidoxime Cl2 appeared to be low, the means were not statistically different from that for the control animals due to an inadvertently low challenge level across all groups.",
            "startOffset": 45751,
            "title": "VX"
        },
        {
            "endOffset": 30297,
            "parents": [],
            "secId": "s0005",
            "sentence": "Overall efficacy was determined specifically in terms of QOL, blood cholinesterase levels in 24-hour survivors, and lethality.",
            "startOffset": 30171,
            "title": "Introduction"
        },
        {
            "endOffset": 53631,
            "parents": [],
            "refoffsets": {
                "bb0230": {
                    "endOffset": 53593,
                    "startOffset": 53574
                },
                "bb0310": {
                    "endOffset": 53545,
                    "startOffset": 53527
                }
            },
            "secId": "s0020",
            "sentence": "In clinical settings, the use of 2-PAM Cl is contraindicated (Wille et al., 2013) or at least controversial (Rosman et al., 2009) against some pesticide intoxication.",
            "startOffset": 53465,
            "title": "Discussion"
        },
        {
            "endOffset": 57517,
            "parents": [],
            "secId": "s0020",
            "sentence": "Since TMB-4 was lethal at 146 \u03bcmol/kg in atropinized guinea pigs in the present study, the treatment dose was reduced to 35 \u03bcmol/kg (20% of the IM LD50) for evaluations.",
            "startOffset": 57348,
            "title": "Discussion"
        },
        {
            "endOffset": 33443,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0040",
            "sentence": "The concentrations of the OP agent stock solutions were checked by gas chromatography (GC) using an Agilent 6890 GC equipped with a flame photometric detector (FPD) in phosphorus mode, prior to and after administration.",
            "startOffset": 33224,
            "title": "Chemical analysis"
        },
        {
            "endOffset": 38623,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "refoffsets": {
                "bb0090": {
                    "endOffset": 38621,
                    "startOffset": 38602
                }
            },
            "secId": "s0050",
            "sentence": "For each animal, the relative AChE activity level (RAAChE) was calculated as the Ellman assay acetylthiocholine turnover rate in a terminal blood sample divided by the turnover rate in the baseline blood sample (Ellman et al., 1961).",
            "startOffset": 38390,
            "title": "OP challenges and oxime therapies"
        },
        {
            "endOffset": 59504,
            "parents": [],
            "secId": "s0025",
            "sentence": "Additionally, none of the oximes evaluated at their TI dose exhibited protection levels matching those exhibited by MMB4 and HL\u00f6-7 at the standardized equimolar dose.",
            "startOffset": 59338,
            "title": "Conclusion"
        },
        {
            "endOffset": 23827,
            "parents": [],
            "secId": "s0005",
            "sentence": "Given the rapid onset of symptoms and toxicity of OP nerve agents, a quick-acting therapeutic regimen that is efficacious over the broad spectrum of OPs is needed.",
            "startOffset": 23664,
            "title": "Introduction"
        },
        {
            "endOffset": 29910,
            "parents": [],
            "secId": "s0005",
            "sentence": "The LD85 was selected as the challenge level across OPs because it maximized the power of the test to discriminate among the oximes in terms of lethality.",
            "startOffset": 29756,
            "title": "Introduction"
        },
        {
            "endOffset": 53464,
            "parents": [],
            "refoffsets": {
                "bb0055": {
                    "endOffset": 53397,
                    "startOffset": 53378
                }
            },
            "secId": "s0020",
            "sentence": "2-PAM Cl, first synthesized in 1955 (Childs et al., 1955), is a monopyridinium oxime with the aldoximide in the 2-position.",
            "startOffset": 53341,
            "title": "Discussion"
        },
        {
            "endOffset": 33123,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0035",
            "sentence": "RS194B was prepared as per supplier instruction by dissolving in a mixture of concentrated (37%, w/w) hydrochloric acid diluted 1:1 (v/v) with distilled water, and adjusting the final oxime solution to pH 7 using 6.25% (w/v) aqueous sodium hydroxide.",
            "startOffset": 32873,
            "title": "Oximes"
        },
        {
            "endOffset": 52413,
            "parents": [],
            "refoffsets": {
                "bb0305": {
                    "endOffset": 52289,
                    "startOffset": 52271
                }
            },
            "secId": "s0020",
            "sentence": "A favored, effective oxime has a relatively high therapeutic/safety index, quickly biodistributes to organs targeted by OPs (Voicu et al., 2013), effectively reactivates inhibited AChE within those target organs, and ensures permanent rapid elimination of the poison.",
            "startOffset": 52146,
            "title": "Discussion"
        },
        {
            "endOffset": 58647,
            "parents": [],
            "secId": "s0020",
            "sentence": "While MINA affords protection against GB and VX, it is a relatively poor reactivator of both AChE and BChE.",
            "startOffset": 58540,
            "title": "Discussion"
        },
        {
            "endOffset": 40653,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The lethality among VX control animals was only 52% (50/96).",
            "startOffset": 40593,
            "title": "Effects of OPs at LD85 challenges in positive control animals"
        },
        {
            "endOffset": 60263,
            "parents": [],
            "secId": "s0110",
            "sentence": "The experimental protocol was approved by the Institutional Animal Care and Use Committee at Battelle.",
            "startOffset": 60161,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 54433,
            "parents": [],
            "refoffsets": {
                "bb0045": {
                    "endOffset": 54307,
                    "startOffset": 54286
                }
            },
            "secId": "s0020",
            "sentence": "A similar study by Cadieux et al. (2010) also indicated less than optimal in vitro reactivation against GA, GB, GF, VX, and Russian VX (VR) relative to HI-6 and MMB4.",
            "startOffset": 54267,
            "title": "Discussion"
        },
        {
            "endOffset": 44573,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "MMB4 DMS also reduced the frequency of salivation/lacrimation, fasciculations, tremors, and prostration as compared to control animals.",
            "startOffset": 44438,
            "title": "Cyclosarin (GF)"
        },
        {
            "endOffset": 24453,
            "parents": [],
            "secId": "s0005",
            "sentence": "This approach is accomplished with the use of the DuoDote\u00ae autoinjector kit (Meridian Medical Technologies\u2122, Columbia, MD; https://www.duodote.com/meridian.aspx#) by trained emergency medical services personnel.",
            "startOffset": 24242,
            "title": "Introduction"
        },
        {
            "endOffset": 45194,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "No improvements in therapy were seen with the TI dose with any of the oximes.",
            "startOffset": 45117,
            "title": "Cyclosarin (GF)"
        },
        {
            "endOffset": 43808,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "As shown in Table 5, only MINA had significant improvement of therapy at the TI dose with zero lethality and animals being asymptomatic at the 24 hour observation.",
            "startOffset": 43645,
            "title": "Sarin (GB)"
        },
        {
            "endOffset": 51809,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Peripheral blood ChE inhibition by GF and VX was significantly mitigated by MMB4 DMS, with total cholinesterase reactivation at 88 to 100%.",
            "startOffset": 51670,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 23663,
            "parents": [],
            "refoffsets": {
                "bb0035": {
                    "endOffset": 23544,
                    "startOffset": 23462
                },
                "bb0075": {
                    "endOffset": 23544,
                    "startOffset": 23462
                },
                "bb0120": {
                    "endOffset": 23544,
                    "startOffset": 23462
                },
                "bb0210": {
                    "endOffset": 23544,
                    "startOffset": 23462
                },
                "bb0330": {
                    "endOffset": 23544,
                    "startOffset": 23462
                }
            },
            "secId": "s0005",
            "sentence": "Organophosphorus (OP) compounds, including pesticides and chemical warfare nerve agents (CWNAs), represent a threat to the general population, not only as possible weapons of terrorism (Okumura et al., 2005; Zurer, 1998; Hubbard et al., 2013; Baker, 2013; Dolgin, 2013), but also as chemicals that could be released from transportation and storage facilities during industrial accidents.",
            "startOffset": 23276,
            "title": "Introduction"
        },
        {
            "endOffset": 27423,
            "parents": [],
            "secId": "s0005",
            "sentence": "The search for a centrally acting oxime to maintain brain AChE activity has produced MINA and RS194B.",
            "startOffset": 27322,
            "title": "Introduction"
        },
        {
            "endOffset": 48074,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "There was also a significant reduction in frequencies of salivation, fasciculations, respiratory distress, and prostration with 2-PAM Cl, HL\u00f6-7 DMS, obidoxime Cl2, or MMB4 DMS.",
            "startOffset": 47898,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 50944,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Obidoxime Cl2 demonstrated the best overall protection for pesticide oxons with significant ChE reactivation, improvement in QOL scores, and survival through the 24 hour period.",
            "startOffset": 50767,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 25150,
            "parents": [],
            "secId": "s0005",
            "sentence": "Additionally, most leading oxime reactivators currently available worldwide, including 2-PAM Cl, are ionized with a hydrophilic bis-pyridinium quaternary backbone.",
            "startOffset": 24987,
            "title": "Introduction"
        },
        {
            "endOffset": 30170,
            "parents": [],
            "secId": "s0005",
            "sentence": "Additionally, those oximes with a safety index greater than 2-PAM Cl, i.e., MMB4 DMS, HI-6 DMS, MINA, and RS194B were also evaluated at an additional \u2018therapeutic dose\u2019 level equal to the median lethal dose (LD50) for the oxime divided by the TI for 2-PAM Cl.",
            "startOffset": 29911,
            "title": "Introduction"
        },
        {
            "endOffset": 39465,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s0055",
            "sentence": "For the impaired and mild signs, if any of the listed signs were present for that classification (e.g., ataxic, miosis), then the score for that classification was assigned a value of 1 regardless of the presence/absence of other signs in that classification.",
            "startOffset": 39206,
            "title": "Quality of life assessment"
        },
        {
            "endOffset": 23946,
            "parents": [],
            "secId": "s0005",
            "sentence": "To provide the most effective therapy, medical countermeasures must be administered as soon as possible post-exposure.",
            "startOffset": 23828,
            "title": "Introduction"
        },
        {
            "endOffset": 45571,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "All animals treated with 2-PAM Cl, MMB4 DMS, HL\u00f6-7 DMS, or TMB-4 survived.",
            "startOffset": 45497,
            "title": "VX"
        },
        {
            "endOffset": 50438,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "GB and VX had much higher ChE reactivation rates and no more than 50% lethality in all oxime-treated groups.",
            "startOffset": 50330,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 48850,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Fig. 2 presents the 24-hour lethality data collated across the eight OPs tested, and illustrates that MMB4 DMS and HL\u00f6-7 DMS offered protection against all OPs except GD, and that 2-PAM Cl and obidoxime Cl2 were effective against all but GD, GF, and (for 2-PAM Cl) GA.",
            "startOffset": 48582,
            "title": "Paraoxon and phorate oxon (PHO)"
        },
        {
            "endOffset": 57922,
            "parents": [],
            "refoffsets": {
                "bb0095": {
                    "endOffset": 57920,
                    "startOffset": 57899
                }
            },
            "secId": "s0020",
            "sentence": "These observations are partially in agreement with those observed by others, where TMB-4 offered high reactivation of rat AChE inhibited by either GA, GB, or VX but not GF (Esposito et al., 2014).",
            "startOffset": 57726,
            "title": "Discussion"
        },
        {
            "endOffset": 27653,
            "parents": [],
            "refoffsets": {
                "bb0010": {
                    "endOffset": 27651,
                    "startOffset": 27561
                },
                "bb0080": {
                    "endOffset": 27651,
                    "startOffset": 27561
                },
                "bb0205": {
                    "endOffset": 27651,
                    "startOffset": 27561
                },
                "bb0235": {
                    "endOffset": 27651,
                    "startOffset": 27561
                },
                "bb0240": {
                    "endOffset": 27651,
                    "startOffset": 27561
                },
                "bb0245": {
                    "endOffset": 27651,
                    "startOffset": 27561
                },
                "bb0250": {
                    "endOffset": 27651,
                    "startOffset": 27561
                }
            },
            "secId": "s0005",
            "sentence": "MINA is a relatively small (molecular weight, or MW = 87.1 Da) AChE reactivator that has been shown to improve survivability against GB (Rutland, 1958; Askew, 1956; Dultz et al., 1957; Myers, 1959; Shih et al., 2009, 2010, 2012).",
            "startOffset": 27424,
            "title": "Introduction"
        },
        {
            "endOffset": 56380,
            "parents": [],
            "secId": "s0020",
            "sentence": "At the TI dose level (245 \u03bcmol/kg) similar results were seen as compared to the equimolar treatment, except with paraoxon where the TI therapy was not effective.",
            "startOffset": 56219,
            "title": "Discussion"
        },
        {
            "endOffset": 58070,
            "parents": [],
            "refoffsets": {
                "bb0270": {
                    "endOffset": 58068,
                    "startOffset": 58048
                }
            },
            "secId": "s0020",
            "sentence": "This oxime is also capable of diffusion across the BBB (Skovira et al., 2010).",
            "startOffset": 57992,
            "title": "Discussion"
        },
        {
            "endOffset": 30762,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": ""
                }
            ],
            "secId": "s1030",
            "sentence": "They were obtained from the U.S. Army Edgewood Chemical Biological Center (Aberdeen Proving Ground, MD).",
            "startOffset": 30658,
            "title": "Organophosphorus compounds"
        },
        {
            "endOffset": 42968,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The oxime therapy in these two groups resulted in the majority of animals returning to normal by 24 h post challenge.",
            "startOffset": 42851,
            "title": "Sarin (GB)"
        },
        {
            "endOffset": 54033,
            "parents": [],
            "secId": "s0020",
            "sentence": "These data are consistent with the less than optimal utility of 2-PAM Cl against GA, GD, and GF observed in this study, and underscore the need for a second generation reactivator for use in the U.S.",
            "startOffset": 53834,
            "title": "Discussion"
        }
    ],
    "docId": "S0041008X14003706",
    "metadata": {
        "asjc": [
            "3004",
            "3005"
        ],
        "authors": [
            {
                "email": "wilhelmc@battelle.org",
                "first": "Christina M.",
                "initial": "C.M.",
                "last": "Wilhelm"
            },
            {
                "email": "snidert@battelle.org",
                "first": "Thomas H.",
                "initial": "T.H.",
                "last": "Snider"
            },
            {
                "email": "babinm@battelle.org",
                "first": "Michael C.",
                "initial": "M.C.",
                "last": "Babin"
            },
            {
                "email": "jettd@ninds.nih.gov",
                "first": "David A.",
                "initial": "D.A.",
                "last": "Jett"
            },
            {
                "email": "platoffg@niaid.nih.gov",
                "first": "Gennady E.",
                "initial": "G.E.",
                "last": "Platoff"
            },
            {
                "email": "dy70v@nih.gov",
                "first": "David T.",
                "initial": "D.T.",
                "last": "Yeung"
            }
        ],
        "doi": "10.1016/j.taap.2014.10.009",
        "firstpage": "254",
        "issn": "0041008X",
        "keywords": [
            "Efficacy",
            "Guinea pig",
            "Intramuscular",
            "Oxime",
            "Toxicity"
        ],
        "lastpage": "265",
        "openaccess": "Full",
        "pub_year": 2014,
        "subjareas": [
            "PHAR"
        ],
        "title": "A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides"
    }
}